A phase II study of intensive consolidation and stem cell mobilization therapy with 
ofatumumab, etoposide, and high -dose ara-C (OVA), followed by autologous stem 
cell transplantation in high -risk patients with relapsed/refractory Diffuse Large B -
Cell Lymphoma  
Protocol Number:  CC #112525  
IND Number:  114,047  
Versio
n Number:  10.0 
Version Date:  January 17, 2017 
Study 
Drugs:  Ofatumumab, etoposide, cytarabine 
Principal Investigator (Sponsor -Investigator)  
Charalambos Andreadis, MD, MSCE  
UCSF Comprehensive Cancer Center  
Co-Investigators  
Lawrence Kaplan, MD  Catherine Smith, MD  Rebecca Olin, MD  
Weiyun Ai, MD  Lloyd Damon, MD  Karin Gaensler, MD  
Aaron Logan, MD, PhD  Thomas Martin III, MD  Peter Sayre, MD  
Neil Shah, MD  Jeffrey Wolf, MD  Gabriel Mannis, MD  
Statistician  
Jimmy Hwang, PhD  
Revision History  
Final  Version 1.0 06-01-2011
Amendment #1  Version 2.0 07-28-2011
Amendment #2  Version 3.0 10-15-2011
Amendment #3  Version 4.0 12-21-2011
Amendment #4  Version 5.0 02-01-2013
Amendment #5  Version 6.0 05-23-2016
Amendment #6  Version 7.0 08-26-2016
Amendment #7  Version 8.0 09-19-2016
Amendment #8  Version 9.0 11-22-2016
Amendment #9  Version 10.0 01-17-2017
Protocol
 Version # 10.0 
Protocol  #112525  01-17-2017
NCT# 01555541
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  ii 
Version  01-17-2017 Protocol  #112525  
Dr. Charalambos  Andreadis   
  
Table  of Contents  
PRINCIPAL INVESTIGATOR  ........................................................................................................................................................ I  
CO-INVESTIGATORS .................................................................................................................................................................. I  
STUDY  SUMMARY  ....................................................................................................................................... 1 
1 INTRODUCTION ................................................................................................................................ 4 
1.1 DLBCL  ......................................................................................................................................... 4 
1.2 I NTENSIVE MOBILIZATION  ................................................................................................................ 4 
1.3 FDG -PET AS A PREDICTIVE  MARKER  IN RELAPSE  ............................................................................. 5 
1.4 O FATUMUMAB  ................................................................................................................................ 5 
1.4.1  Safety ....................................................................................................................................... 6 
1.4.2  Efficacy  .................................................................................................................................... 7 
2 STUDY OBJECTIVES ........................................................................................................................ 9 
3 STUDY DESIGN  ................................................................................................................................. 9 
3.1 G ENERAL DESIGN  .......................................................................................................................... 9 
3.2 P RIMARY STUDY  ENDPOINTS  .......................................................................................................... 9 
3.3 S ECONDARY  STUDY  ENDPOINTS  ..................................................................................................... 9 
4 SUBJECT  SELECTION  AND  WITHDRAWAL ................................................................................. 11 
4.1 I NCLUSION CRITERIA ..................................................................................................................... 11 
4.2 E XCLUSION  CRITERIA  ................................................................................................................... 11 
4.3 S UBJECT RECRUITMENT  AND  SCREENING  ...................................................................................... 11 
4.4 E ARLY WITHDRAWAL  OF SUBJECTS  ............................................................................................... 11 
4.5 D ATA COLLECTION  AND FOLLOW -UP FOR  WITHDRAWN SUBJECTS  ................................................... 11 
5 ON STUDY  EVALUATION  ............................................................................................................... 11 
5.1 R EGISTRATION  ............................................................................................................................. 11 
5.2 S ALVAGE  RESPONSE  ASSESSMENT  ............................................................................................... 11 
5.3 D AY 0 OF OVA ............................................................................................................................. 11 
5.4 A LL OTHER  DAYS  OF OVA ............................................................................................................. 11 
5.5 D AY 42 E VALUATION  (+/- 4 DAYS ) ................................................................................................. 11 
5.6 CBV A DMINISTRATION  .................................................................................................................. 11 
5.7 D AY +30’ AND  +60’ EVALUATION  (+/- 4 DAYS ) ................................................................................ 11 
5.8 D AY +90’ EVALUATION  (+/- 4 DAYS )............................................................................................... 11 
5.9 M ONTH 6, 12, AND  24 E VALUATION  (+/- 4 WEEKS ) .......................................................................... 11 
5.10 A T TIME OF SUSPECTED  RELAPSE /PROGRESSION  .......................................................................... 11 
6 FOLLOW -UP PHASE  ....................................................................................................................... 11 
7 TREATMENT REGIMEN  .................................................................................................................. 11 
7.1 I NTENSIVE MOBILIZATION  REGIMEN  (OVA)  .................................................................................... 11 
7.1.1  Ofatumumab
 Administration  at 1000mg IV on days  0,7,14,  and 21.  ..................................... 11 
7.2 PERIPHERAL BLOOD  STEM  CELL  (PBSC)  COLLECTION  ..................................................... 11 
7.3 H IGH-DOSE THERAPY  WITH  STEM  CELL RESCUE (CBV)  ................................................................. 11 
7.4 O PTIONAL  RADIOTHERAPY  ............................................................................................................ 11 
8 MEASUREMENT  OF EFFECT  ......................................................................................................... 11 
8.1 D EFINITION  OF ADEQUATE STEM  CELL COLLECTION  ....................................................................... 11 
8.2 D EFINITION  OF ENGRAFTMENT  ...................................................................................................... 11 
8.3 L YMPHOMA RESPONSE ASSESSMENT  (REVISED IWG CRITERIA [12]) ................................................ 11 
8.4 S URVIVAL -TIME  PARAMETERS  ........................................................................................................ 11 
9 SAFETY AND  ADVERSE  EVENTS  ................................................................................................. 11 
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  ii 
Version  01-17-2017 Protocol  #112525  
Dr. Charalambos  Andreadis   
 OVA in High -Risk Relapsed or  Refractory  DLBCL  Page iii 
9.1 S AFETY DEFINITIONS  .................................................................................................................... 11 
9.2 T IME PERIOD AND FREQUENCY OF  DETECTING  AND REPORTING  SAE S ........................................... 11 
9.3 S PECIAL REPORTING  CONSIDERATIONS  ......................................................................................... 11 
10 STUDY DRUG  AND  CHEMOTHERAPEUTIC AGENTS  ................................................................... 11 
10.1 O FATUMUMAB  (ARZERRA ) ............................................................................................................. 11 
10.2 E TOPOSIDE  (VESPID ®; VP-16) ..................................................................................................... 11 
10.3 G- CSF (FILGRASTIM ; NEUPOGEN ®) .............................................................................................. 11 
10.4 C YTARABINE (CYTOSAR -U®; ARA-C; CYTOSINE ARABINOSIDE ) ....................................................... 11 
11 STATISTICAL  CONSIDERATIONS  ................................................................................................... 11 
11.1 S AMPLE SIZE ............................................................................................................................... 11 
11.2 S TATISTICAL  METHODS  ................................................................................................................. 11 
11.3 A CCRUAL AND ESTIMATED  DURATION  OF STUDY  ............................................................................ 11 
11.4 DLBCL  SUBTYPING  ...................................................................................................................... 11 
11.5 M INIMAL RESIDUAL  DISEASE TESTING  ........................................................................................... 11 
11.6 D ATA SAFETY  MONITORING  PLAN .................................................................................................. 11 
12 DATA MANAGEMENT  AND  STUDY  TERMINATION  ...................................................................... 11 
12.1 D ATA AND  PROTOCOL  MANAGEMENT  ............................................................................................. 11 
12.2 T ERMINATION  OF STUDY  ............................................................................................................... 11 
13 STUDY  FINANCES  ............................................................................................................................ 11 
13.1 F UNDING  SOURCE  ........................................................................................................................ 11 
13.2 C ONFLICT OF  INTEREST  ................................................................................................................ 11 
14 REFERENCES  ................................................................................................................................... 11 
15 ATTACHMENTS  ................................................................................................................................ 11 
15.1 S TUDY  PROCEDURES  ........................................................................................................................ 11 
15.2 C ALCULATION  OF SAAIPI  ................................................................................................................... 11 
15.3 H IGH DOSE  THERAPY  WITH  STEM  CELL RESCUE  (CBV)  ...................................................................... 11 
OVA in High -Risk Relapsed/Refractory DLBCL  Page 1  
 Study Summary  
 
Title A phase II study  of intensive consolidation and stem  cell mobilization  therapy  
with Ofatumumab,  etoposide, and high -dose  ara-C (OVA),  followed by  
autologous stem  cell transplantation in  high- risk patients  with relapsed/refractory  
Diffuse  Large B- Cell Lymphoma 
Study  Design Phase II,  single  institution pilot  study  
Study  Duration 24 months  accrual,  24 months  followup  
 
 
 
 
 
 
 
 
 
 
Objectives Primary  Objective:  
To demonstrate the ability  of Ofatumumab  in combination with  etoposide and 
cytarabine to mobilize  peripheral blood stem  cells and lead to a high compelte 
metabolic  response rate prior to autologous stem  cell transplantation in rituximab  
pre-treated patients  with high- risk relapsed or  refractory  DLBCL.  
 
Secondary  Objectives:  
2.2.1  To evaluate stem  cell engraftment following successful  mobilization.  
2.2.2  To determine PFS following treatment  with Ofatumumab  in combination 
with etoposide and high -dose ara- C (OVA)  and subsequent  autologous stem  cell 
transplantation.  
2.2.3  To measure the effect  of OVA on  other clinically  meaningful  endpoints.  
2.2.4  To measure the FDG -PET conversion rate from PR  to CR  following  OVA  
and its  association  with clinical outcomes.  
2.2.5  To examine  potential relationships between Ofatumumab concentration 
and clinical outcomes.  
2.2.6  To study  the safety  and tolerability of  OVA.  
2.2.7  To store tumor  tissue for future molecular  subtyping.  
2.2.8  To evaluate minimal -residual  disease testing in  the setting of  
transplantation.  
Number of Subjects  24 patients  
 
 
 
 
 
 
 
 
 
 
Main Eligibility  
Criteria  KEY INCLUSION  CRITERIA  
 
Diagnosis of CD20+  WHO diffuse  large B -cell lymphoma  or primary  mediastinal  
B-cell lymphoma.  Transformation of previously -diagnosed low -grade lymphoma 
is excluded.  
Refractory to  or relapse following a rituximab/anthracycline first-line regimen 
High-risk disease  as defined  by one of  the following:  
• First relapse after CR within 12 months  of initiation  of front -line 
therapy  
• Less than CR  to front -line therapy  
• sAAIPI  of 2 or higher at the time of relapse (see attachment 14.2)  
 
Receipt of  no more than three prior chemotherapy  regimens.  Monoclonal  
antibody  therapy  and involved field  radiotherapy are not  included in  this number.  
Prior use  of ofatumumab  is allowed if  there has  been no disease progression 
following  that therapy (i.e. ofatumumab- based salvage  regimens  allowed)  
 
KEY EXCLUSION  CRITERIA  
 
Progression  following  prior ofatumumab  salvage  therapy  
 
Version 01-17-2017 Protocol  #112525  
Dr. Charalambos  Andreadis  
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  2 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis   
  
 
  
Active central  nervous  system  or meningeal involvement by lymphoma.  Patients  
with a history of  CNS or  meningeal  involvement  must  be in a documented 
remission  by CSF evaluation and contrast  MRI imaging  for at least  3 months  
prior to study  entry.  
 
Bone marrow  involvement  with more than or equal  to 15% lymphoma cells  
following  salvage therapy.  
 
Evidence of myelodysplasia on any bone marrow  biopsy  prior to initiation  of 
therapy.  
 
Known HIV infection  
Positive  serology  for Hepatitis B (HB) defined as a positive test for  HbsAg and a 
detectable HBV  DNA  viral load.  If negative for HBsAg but  HBcAb  positive  
(regardless  of HBsAb status),  a HBV DNA test will  be performed and if positive 
the subject  will be excluded.  If HBV DNA  is negative,  subject  may be included 
but must  undergo at least every  2-month HBV DNA PCR testing from  the start of 
treatment  during the treatment  course.  Prophylactic  antiviral  therapy  may be 
initiated at the discretion of  the investigator.  
Positive  serology  for hepatitis C (HC)  defined as  a positive test  for HCAb,  in 
which case  reflexively  perform  a HCV  PCR to  confirm  the result  
 
Receipt of  live virus  vaccination  within 4 weeks prior  to planned initiation of study  
treatment.  
 
Study  Product,  
Dose,  Route,  
Regimen  Ofatumumab 1000 mg IV on  days  0,7,14,21 
Given  concurrently  with: 
Etoposide 10 mg/Kg IV  over 24 hours  daily,  days  1-4 
Cytarabine 2000 mg/m2 IV twice daily,  days  1-4 
 
 
 
 
 
 
 
 
 
 
Statistical  
Methodology   
This is  a single -institution,  single -arm, open -label  Phase II study  of Ofatumumab  
in combination with  etoposide and high- dose  cytarabine as  an intensive  
consolidation  and stem  cell mobilization regimen in patients with 
relapsed/refractory diffuse large B- cell lymphoma.  The primary  efficacy  endpoint  
of the study  is the mobiliz ation- adjusted complete response rate (maCR)  which  
is defined as  the proportion of patients achieving complete response  to the 
treatment  upon successful  stem  cell mobilization,  defined as at  least 2 x10^6  
CD34+cells/Kg of  actual body  weight. Secondary  endpoints include time to 
neutrophil and platelet engraftment following ASCT, PFS in this high- risk patient  
population and other  survival -time measures  of clinical efficacy,  i.e. OS, TTP,  
EFS,  and CR/Pr proportion at day +90.  Our study  will also measure the FDG - 
PET conversion rate from PR to CR following OVA  and correlate post-OVA PET 
results  with PFS, TTP, and OS. We will examine potential  relationships  between 
Ofatumumab concentration at selected time points and PFS, TTP, OS.  We will 
perform MRD  testing at  baseline, at the time of stem  cell collection,  and following 
ASCT, and will correlate the results  to clinical endpoints.  Finally,  safety  will be  
evaluated with regard to  infusion -related reactions,  B-cell number,  
hypogammaglobulinemia,  and long- term hematologic  toxicity.  
 
Patients  who have received  a single  infusion  of study  drug (day  0 of OVA)  will be  
included in the statistical  analyses.  We are planning to accrue 24 subjects  over 
the course  of 2 years  with an  additional  2-year follow -up.  In terms  of the 
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  3 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis   
  
 
composite primary endpoint,  the historical  CR rate after 2 cycles  of salvage 
therapy  among high risk,  rituximab  refractory  patients  is between 25%  and 50%  
of the overal responses  (i.e CR/(CR+PR).[8,  19, 20]  Furthermore,  the chance of  
a mobilization failure  among  complete an dpartial  responders  observed in the 
CORAL study  is 15%.[9]  We thus expect  the null  value  of the composite 
endpoint of  maCR  to be  25% (~40%  CR-15% mobilization failure).  Given  the 
excellent historical  CR rates  with intensive consolidation and the very  low risk of 
mobilization failures,  we expect  the alternative maCR rate to be 50%.  Based on 
the exact probability  with type I error of 10%  and 1 -sided  test, a sample  size of 
N=24 in the single  arm study  will have  > 80% power  to detect the maCR  rate for 
the following  hypothesis:  H0: p0<25%  (40%CR/15%mobilization- failure)  vs Ha: 
p1>50%  (55%CR/5%mobilization- failure under OVA).  The following table shows  
statistical  power for the test of the  null hypothesis under  the assumed maCR  of 
25% and for various  mobilization- adjusted complete response rates  with 24 
subjects  (alpha=10%  under 1- sided exact test):  
 
maCR  rate Statistical  Power  
25% vs 40% 51% 
25% vs 45% 70% 
25% vs 50% 84% 
25% vs 55% 93% 
25% vs 60% 97% 
 
An interim analysis for  futility  and safety  will be performed when 12 subjects  are 
enrolled. We  will define  the futility  as >50%  stem  cell mobilization failure as  
excessive and unacceptable.  If six or fewer  (< 50%)  subjects  have adequate 
stem  cell mobilization,  the enrollment  will not  continue and the study  will be  
closed for treatment  futility.  Otherwise  we will enroll 12  additional patients to  
complete study  for full maCR  efficacy  analysis. At  the same  time as the interim  
analysis for futility, we will also perform  an interim evaluation for safety, which is  
defined as  >30% SAE as too  toxic and unacceptable.  If 4 or more (>30%)  of the 
first 12 patients  treated are observed to have protocol -defined unacceptable 
toxicity, the study  will be closed  for lack of  safety. If the stem  cell collection 
success rate is  less than 50%,  the probability  of early  stopping due to futility  is 
61%. If  the toxicity  rate is greater  than 30%,  the probability of  early  stopping due 
to safety  is 64%.  
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  4 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis   
  
 
 
1 Introduction  
 
This document  is a protocol  for a human research study.  This study  is to be conducted according to US 
and international  standards  of Good  Clinical  Practice  (FDA  Title 21 part 312 and International  Conference 
on Harmonization guidelines),  applicable government  regulations  and Institutional  research policies  and 
procedures.  
 
1.1 DLBCL  
 
Diffuse  Large B- cell Lymphoma (DLBCL)  is the most  common  lymphoma  worldwide.  Even  though 
rituximab/anthracycline- containing  chemotherapy  (e.g. R-CHOP)  can cure a significant  proportion of 
patients  with this disease  in the modern era, approximately  40% are either  refractory  to  front-line 
treatment  or relapse following  therapy.[1- 3] The standard of care for these relapsed/refractory  patients  
involves  salvage chemotherapy  (e.g. R-ICE, R-DHAP,  R-ESHAP,  etc) followed by autologous  stem  cell 
transplantation (ASCT)  in patients  who are chemosensitive  to salvage.[4]  
 
The obstacles  to curing patients  following  a relapse  are several.  These  include:  1) poor response to 
salvage  therapies,  and thus ineligibility  for subsequent  ASCT;  2) inadequate mobilization  of stem  cells in 
these  densely  pre-treated patients;  and 3) residual  disease following  salvage therapy.[5,  6] Historically,  
patients  at high-risk for treatment  failure  include  those  refractory  to initial therapy  or relapsed within  12 
months  of treatment  initiation  [7] and those  with a high age-adjusted international  prognostic  index  at the 
time of relapse (sAAIPI).  [8] More recently,  the international  CORAL  study  has also identified prior 
treatment  with rituximab  to be significantly  associated with inferior  response rates  to rituximab -containing 
salvage therapy  and inferior  long- term survival outcomes  after ASCT.[9]  This effect  appears  to be limited  
to those patients  who relapse within  12 months  of initiation  of therapy,  and 2- year PFS in this population  
starting from initiation  of salvage  therapy  was only 15%.  Out of the 187 patients  in that group,  only 68 
(36%)made it to transplantation,  and this subgroup  had a 2- year PFS of 39% following  ASCT.  [9] 
Additionally,  15% of responding patients  didn’t  make  it to ASCT  solely  due to inadequate stem  cell 
collection.  
 
1.2 Intensive  Mobilization  
 
We have developed an intensive approach for treating relapsed patients  with high- risk aggressive 
lymphoma prior to transplantation.  [10] Following  2-3 cycles  of salvage therapy  at relapse,  high- risk 
patients  undergo an additional  cycle  of therapy  with either  etoposide,  cyclophosphamide,  and rituximab  
(CER)  or etoposide,  cytarabine,  and rituximab  (EAR)  to further  decrease tumor  burden and to provide in- 
vivo purging of the stem  cell graft.  Stem  cells are then collected following  this regimen as opposed to 
standard mobilization (high -dose cyclophosphamide  or R-ICE) used for the low-risk patients.  In our 
reported cohort,  treatment  with intensive mobilization  was well-tolerated and resulted in excellent  stem - 
cell mobilization with no collection  failures.  Moreover,  event -free survival among the high- risk patients  
with DLBCL  going to ASCT  after CER  or EAR was comparable  to that of low-risk patients  treated with 
standard  mobilization  (Figure  1a) and overall  survival  was significantly  improved (Figure  1b). In this high- 
risk cohort,  our observed 4- year EFS and OS rates  are 67% and 76% respectively,  comparing  very 
favorably  to the reported rates  from CORAL (4-year PFS 39%).[10]  
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  5 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis   
  
 
 
 
1.3 FDG -PET as a predictive marker  in relapse  
 
PET imaging using fluorodeoxyglucose (18F) has been conclusively  shown  to predict  response duration,  
progression -free, and overall  survival  at the completion of first-line therapy  in patients  with DLBCL  and 
other  lymphomas.[11]  It has consequently  been incorporated in the response assessment  criteria  for 
lymphoma and has become the standard of clinical care.[12]  Several  studies  are underway  to address  
the utility of interim  PET in tailoring  frontline  therapy for selected  groups  of patients.  
In the relapse setting,  there is evidence  to suggest  that FDG -PET assessment  following  salvage 
therapy  is also predictive of outcomes  following  ASCT.  [13-18] Specifically,  patients  in PET+  PR prior to 
ASCT  have long- term disease -free survival  rates  in the order  of 30-40% compared  to 70-80% for the 
PET- CR patients.  Historically,  PET response data are limited  in the setting of salvage therapy  for high- 
risk patients  with DLBCL.  Based on the available studies,  we believe the PET-negative CR rate following  
2 cycles  of salvage to be between 25% and 50% among overall  responders  in this high-risk group  of 
patients  [CR/(CR+PR)=  25-50%].[8,  19, 20] We hypothesize that if we can improve  the PET- CR rate 
with intensive consolidation therapy  and thus achieve a PET-negative response prior to ASCT,  we will 
improve  long- term outcomes  in this group  of patients.  The ability  of tailored  therapy  for PET+  patients  to 
improve  long- term transplantation- related outcomes  has been validated in relapsed Hodgkin Lymphoma.  
[21] 
 
1.4 Ofatumumab  
 
Ofatumumab  is a type I, human  IgG 1k antibody  that binds  to a novel  epitope of CD20  that encompasses  
the small extracellular  loop and the N- terminal  region  of the second large extracellular  loop.[22]  It binds  
to a different  epitope from rituximab and because  of the avidity  and proximity  of CD20  binding,  it may lead 
to better  complemet -dependent  cytotoxicity  (CDC).[22,  23] Although the mode of action  of the two mAbs  
is similar,  nonclinical  data indicate that ofatumumab may have a greater  potential  for effector  activity,  
particularly  on tumor  cells expressing low levels  of CD20.  Another  potential  advantage is the predicted 
low level of immunogenicity  for a human anti-human  antibody  (HAHA)  response to ofatumumab in 
comparison to the human anti-chimeric  antibody  (HACA)  response  to rituximab.  An in vitro human tissue  
cross- reactivity  study  has confirmed that ofatumumab  binding is restricted to B cells within  the peripheral  
blood circulation and human  lymphoid tissues,  suggesting there is little likelihood of non- 
pharmacologically  mediated effects.[24]  
a 
 b 
p=NS  
 p=0.04  
Figure  1: Event -free (a) and overall  (b) survival  among  43 patients  with DLBCL  who 
underwent   autologous   stem  cell  transplantation  per  protocol.  Reproduced  from 
Damon  et al [10] 
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  6 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis   
  
 
1.4.1 Safety 
 
1.4.1.1  Preclinical  Studies  
Intravenous  (IV) administration  to monkeys  for up to 7 months  profoundly  decreased circulating  B cells 
and resulted in moderate  germinal  center  and follicular  atrophy  in the lymph  nodes,  Peyer’s  patches  and 
spleen.  Following  clearance of ofatumumab,  repletion of B cell counts  and a reversal  of the tissue 
changes  noted during the study  were  observed.  There  were  no other  ofatumumab- related systemic  
effects  (including  effects  on the delayed type hypersensitivity  response)  or histopathological  changes  in 
monkeys  following  chronic  exposure to ofatumumab.  However,  a minor  reduction in the magnitude of the 
immunoglobulin G (IgG)  response to the keyhole  limpet  haemocyanin (KLH)  antigen was noted in 
monkeys  dosed at 20 and 100 mg/kg.  
 
There  were  5 unscheduled deaths  in the intravenous  7-month  repeat  dose study.  Three out of 42 
monkeys  succumbed to a probable C. jejuni  infection;  a common  yet problematic  fecal -oral transmitted  
pathogen in monkeys.  This infection  was not considered to be ofatumumab treatment -related and no 
increase  in susceptibility  to infection  has been reported in the clinical studies.  Haemolytic  anaemi a 
occurred in 2 out of 42 monkeys  in the 7- month  study.  Both of these  monkeys  had a positive  direct  
Coombs’  test indicative  of the presence  of anti-drug antibodies  (ADAs).  It is most  likely  that the hemolytic  
anemia was due to a strong  ADA response  to ofatumumab,  which  induced immune complex  formation.  
Binding of immune complexes  to the surface of the red blood cells is thought  to have resulted in 
sequestration  of the coated red cells in the spleen causing  the hemolytic  anemia.  ADAs  have been  
detected in several  monkey  toxicity  studies  following  both IV and SC administration.  However,   no 
toxicities  directly  associated with the ADAs  have  been reported and an ADA response in monkeys  is not 
considered indicative of an ADA response in humans.[25]  
 
No maternal  toxicity,  adverse  effects  on embryofetal  development  or teratogenicity  occurred  in  the 
monkey  embryofetal  development  study  at doses  up to 100 mg/kg.  The effect on human pregnancy  is 
unknown.  Precautions  will be undertaken to avoid pregnancy  and adequate contraception will be used  
while  using ofatumumab.  
 
 
1.4.1.2  Clinical Studies  in Humans  
Over  1000 patients  have been exposed to ofatumumab  in hematologic  malignancy  clinical trials.  Infusion  
reactions  in the IV program  are common  adverse  events  (AEs)  that are generally  mild to moderate in 
severity,  and have been mitigated by premedication and slower  IV administration.  Severe  infusion 
reactions  have been reported,  and have occasionally  led to temporary  interruption or withdrawal  of 
ofatumumab.  
 
Infectious  events  including  lower  respiratory  tract infections  and cytopenias  that include neutropenia,  
anemia,  and thrombocytopenia have been observed in oncology  trials  with ofatumumab,  but these events  
are commonly  reported with the diseases  under  study  and/or  other  concomitant  therapies.  Neutropenia  
and serious  infections  have also been reported in RA studies,  but these generally  occurred at a similar  
frequency  between the ofatumumab and placebo groups.  
 
A total of 59% (48/81)  of patients  had infusion- related  reactions  after the start of and up to 24 hours  after 
any of the 8 ofatumumab infusions.  Investigators  considered  infusion reactions  to be drug- related in 44% 
(36/81)  of patients.  Infusion  reactions  primarily  occurred during Infusion  1 (40%)  and Infusion  2 (22%),  
and decreased with subsequent  infusions.  The most  common  infusion- related reactions,  regardless  of 
causality,  were  rash (10%),  anaphylactoid events  (9%),  hypersensitivity  (7%),  edema (7%),  anorexia  
(6%), nausea (6%), and c ardiac events  (6%).  Infusion -related reactions were  predominantly  (96%) Grade  
1-2 in severity.  Four subjects  (5%)  experienced infusion -related reactions  ≥ Grade 3 in severity  (2 
subjects  anaphylactoid events,  1 subject  bradycardia and convulsion  1 subject  facial  edema,   rash,  
nausea,  and altered taste). All  subjects  recovered.[24]  
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  7 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis   
  
 
In study  GEN415 [26], a total of 81 subjects  diagnosed with DLBCL  were  treated  with 8 weekly  infusions  
of ofatumumab  (1st dose:  300 mg; 2nd – 8th dose:  1000 mg). All subjects  received oral acetaminophen  
and IV antihistamine  prior to each  infusion  and IV glucocorticoid  prior to the first and second infusions.  
The protocol  defined  AE reporting period was from the first infusion  (Visit  2/Week  0) to Visit 18 (Month 24 
of follow -up) or time of withdrawal  (treatment  and follow -up). SAEs  were  reported through Month 60 
(treatment,  follow -up and extended  follow -up). The safety  cut-off for the interim  safety  analysis  was 28 
Feb 2010.  
 
Of all 81 subjects,  78 (96%)  experienced AEs during treatment  and follow -up. The most  commonly  
reported  AEs are shown below.  The most  common  AEs experienced overall  were  diarrhea (14 subjects,  
17%),  fatigue (12 subjects,  15%),  edema,  peripheral  (each 12 subjects,  15%),  neutropenia (11 subjects,  
14%),  abdominal  pain,  constipation,  nausea (each 10 subjects,  12%),  pyrexia,  anemia,  leukopenia (each  
9 subjects,  11%),  and dyspnea,  anorexia (each 8 subjects,  10%).  
 
AEs experienced by Greater  than or equal  to 10% of  DLBCL  
 
 
 
1.4.1.3  Pharmacokinetics,  Product  Metabolism,  and Pharmacodynamics in Humans  
Pharmacokinetic  data are curr ently  available from four completed studies  (Study  001, Study  402, Study  
403, and Study  148),  three  concluded  studies  (Study  405, Study  407, and Study  GEN414/OMS115102 
[48-week  interim  analysis  completed]),  and four ongoing studies  (Study  406, Study  409, Study  
GEN410/OFA110635 [completed to 24 weeks],  and Study  OFA110867 [Day 169 interim  analysis  
completed]).  Ofatumumab  was administered by IV infusion  in all studies  except  Study  OFA110867,  in 
which  it was given by  SC injection.  
 
Measurable concentrations  of ofatumumab  were  detected in all actively  treated subjects,  except  for some 
subjects  who received  low doses  in Study  OFA110867.  After  repeated  IV administration,  clearance and 
volume  of distribution values  were  low, and half-life values  were  long for ofatumumab,  as seen with other  
monoclonal  antibodies.  Statistically  significant  increases  in AUC,  Cmax,  and t½ values  and decreases  in 
CL values  were  found between the first and the last infusion.  These  findings  are likely  due to the rapid  
and sustained  depletion of CD20+  B cells after first infusion,  leaving a reduced number  of B cells 
available for the antibody  to bind at the following  infusions.  Subcutaneous  administration of a single  dose 
of ofatumumab  ≥30 mg in subjects  with RA  similarly  resulted  in rapid  and sustained B- cell depletion.  
 
1.4.2   Efficacy  
 
1.4.2.1 Follicular  Lymphoma  
As of 21 December  2010,  efficacy  results  are available from one completed  study  (Study  Hx-CD20 -001) 
and 2 concluded studies  in Follicular  Lymphoma (FL);  Study Hx -CD20 -405 and Study Hx -CD20 -409 [24].  

OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  8 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis   
  
 
In Study  Hx-CD20 -001 (N=40),  overall  response (OR)  in evaluable subjects  with FL in all ofatumumab 
dose groups  was 41% (300 mg, n=10:  63%;  500 mg, n=10:  33%;  700 mg, n=10:  20%;  and 1000 mg, 
n=10:  50%)  and included  4 (10%)  subjects  with complete response (CR),  3 (8%)  subjects  with complete 
response unconfirmed (CRu),  and 8 (20%)  subjects  with partial  response (PR).  A total of 19 (48%)  
subjects  had stable disease (SD),  and 3 subjects  had progressive disease (PD).  The median time to 
progression (TTP) for all subjects  was 8.8 months and the median duration of response was 29.9 months.  
The median time to next  FL therapy was not  reached during the study.  
 
In Study  Hx-CD20 -405, 116 subjects  were  treated with two dose levels  (500 mg, n=30;  1000 mg, n=86)  of 
single- agent  ofatumumab.  The overall  response rate (ORR)  in the total population was 11%.  This group  
of subjects  was highly  refractory  with 65% refractory  to their last chemotherapy.  Subjects  in the study  had 
previously  received a median of 4 prior treatment  regimens.  The 1000 mg dose  group (n=86)  
demonstrated an ORR  of 10% (1 CR, 8 PR). In addition,  50% of subjects  in the 1000 mg treatment  arm 
had SD. The ORR among  subjects  in both treatment  arms  who were  refractory  to prior rituximab 
monotherapy  (n=27)  was 22%.  The ORR  rate in subjects  refractory  to rituximab  in combination with 
chemotherapy  was 7%, and the ORR among subjects  refractory  to rituximab  maintenance was 9%. The 
median duration of response was 6 months,  and the median progression free survival  (PFS)  for all 
subjects  was 6 months.  
 
In Study  Hx-CD20 -409 (N=58),  subjects  with previously  untreated FL were  randomized to two dose levels  
of ofatumumab  in combination with CHOP  (cyclophosphamide,  doxorubicin,  vincristine,  and prednisone):  
300 mg of ofatumumab  (cycle  1) followed by 500 or 1000 mg of ofatumumab  (cycles  2-6), in combination  
with CHOP,  every  3 weeks  for 6 cycles.  Results  demonstrated an ORR of 90%,  CR 24%,  and CRu 45% 
in the 500 mg group (n=29).  In subjects  treated with 1000 mg of ofatumumab  (n=29),  the ORR  was 100%  
including 38%  CR and 17% CRu.  Two subjects  had SD  and 1 subject  had PD.  
 
1.4.1.2    Diffuse large  B-cell lymphoma  
Cilessen  et al demonstrated  that DLBCL  cell lines and rituximab -resistant  DLBCL  cells from 10 patients  
were  effectively  killed  by ofatumumab.  [27] As of 21 December  2010,  efficacy  results  are available from 1 
conculded study  in relapsed  Diffuse  Large B- Cell Lymphoma (DLBCL)  (GEN415/OMB111776). In study  
GEN415 [26], patients  (n=81)  with relapsed DLBCL,  ineligible  for transplant  or relapsed after autologous  
transplant  were  treated with 300mg,  followed by  seven weekly 1000mg infusions  of ofatumumab  as single  
agent.  Notably,  the median  number  of prior therapies  in that study  was 3 and 96% of the patients  had 
received prior treatment  with rituximab.  The ORR  for the single agent  was 11%  (3 CR and 6 PR). [26]  
 
1.5 Study  Rationale  and Selection  of Primary  Endpoint  
Patients  with relapsed DLBCL  who are refractory  to or relapse within  12 months  of first-line rituximab - 
based therapy,  have poor  outcomes with  conventional  approaches  to autologous  stem cell  transplantation  
as detailed above.  We hypothesize that the intensive  mobilization strategy  developed at our institution  
can overcome some  of the obstacles  to successful  ASCT  by both eliminating  residual  disease following  
salvage therapy  and by facilitating  stem  cell collection.  Even  though there  is clinical experience in the 
cooperative group setting with intensive pre-ASCT  mobilization,  it has never  been prospectively  validated 
in DLBCL  and concerns  exist as to its ability  to improve outcomes  with ASCT  in this high-risk, and heavily  
pretreated group of patients.  Furthermore,  most  patients  in our registry  treated with intensive mobilization  
were  rituximab -naïve and the findings  may not translate in the rituximab -refractory  population.  We also 
believe that ofatumumab,  a novel  monoclonal  antibody  against  a distinct  CD20  epitope may in fact 
overcome  rituximab  resistance  in DLBCL  patients  and through more  effective  CDC  may eliminate  minimal  
residual  disease in the patient and contaminating tumor cells in the stem  cell graft.  
 
We thus propose  a pilot phase II study  that will incorporate ofatumumab instead of rituximab in 
combination with etoposide and cytarabine (OVA)  as an intensive mobilization regimen in high- risk 
patients  with DLBCL  undergoing ASCT.  We have chosen our primary  endpoint,  mobilization -adjusted  
PET negative  CR rate, as a criterion  for maximum  benefit  prior to ASCT,  i.e. improving mobilization rates  
compared to traditional  mobilization and increasing the depth of response.  This is consistent  with the 
primary  endpoint  of the CORAL  study,  i.e. mobilization- adjusted response rate.   If our approach is 
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  9 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis   
  
 
successful,  we would plan to validate this strategy  in a multi- institution  / cooperative group setting in this 
patient  population.  
 
 
2 Study Objectives 
2.1 Primary  Objective:  To demonstrate the ability  of Ofatumumab in combination with etoposide 
and cytarabine to mobilize  peripheral  blood stem  cells and lead to a high complete metabolic  response  
rate prior to autologous  stem  cell transplantation  in rituximab  pre-treated  patients  with high- risk 
relapsed or refractory  DLBCL.  
 
2.2 Secondary  Objectives:  
2.2.1  To evaluate stem  cell engraftment following successful  mobilization.  
2.2.2  To determine PFS following  treatment  with Ofatumumab in combination with etoposide and high- 
dose ara-C (OVA)  and subsequent  autologous stem  cell transplantation.  
2.2.3  To measure the effect  of OVA on  other clinically  meaningful  endpoints.  
2.2.4  To measure the FDG -PET conversion rate from PR to CR following  OVA and its association with 
clinical outcomes.  
2.2.5  To examine  potential  relationships  between Ofatumumab concentration and clinical outcomes.  
2.2.6  To study  the safety  and tolerability of  OVA.  
2.2.7  To store tumor  tissue for future molecular  subtyping.  
2.2.8  To evaluate minimal -residual  disease testing in  the setting of  transplantation.  
 
 
3 Study Design  
3.1 General  Design  
This is a single -institution,  single- arm, prospective  phase II study.  Patients  with high- risk DLBCL  (defined  
as either  achieving less than CR to initial rituximab -containing  therapy  or relapsing  within  12 months  of 
initial therapy)  will be enrolled on this study  and will undergo staging prior to receiving intensive 
mobilization  with ofatumumab,  etoposide,  and high-dose ara-C (OVA).  Following  successful  stem  cell 
collection,  patients  will proceed to standard autologous  transplantation with cyclophosphamide,  BCNU,  
and etoposide  (CBV)  preparative regimen.  Response evaluation will occur  after salvage  therapy,  
following  intensive  mobilization  therapy  (d42),  at day +90 after ASCT,  and at 6, 12 and 24 months  
thereafter.  Event -free, progression -free, and overall  survival  will also be assessed  until 48 months.  The 
primary  study  endpoint  is mobilization- adjusted complete metabolic  response rate (maCR)  following  OVA.  
Subjects  who are not chemosensitive to salvage  therapy  (i.e. do not achieve a PR or CR) will be re- 
evaluated after an additional  salvage regimen.  If they are still not chemosensitive at this point,  they will 
be withdrawn from  the study  and replaced.  
 
3.2 Primary  Study  Endpoints  
 
To demonstrate the ability  of OVA to both: 
i) mobilize  at least  2 x10^6  CD34+cells/Kg of actual  body  weight  peripheral  blood stem  cells,  and 
ii) result  in a metabolic  CR on day  42 assessment  
 
3.3 Secondary  Study  Endpoints  
3.3.1  Estimate additional  mobilization  parameters:  Percent  of patients  collecting  ≥2, ≥5 and ≥10 x10^6  
CD34+cells/Kg with one collection;  median # collections  to achieve ≥2, ≥5 and ≥10 x10^6  CD34+cells/Kg;  
Time  to neutrophil and platelet engraftment following ASCT.  
3.3.2  To determine PFS following  treatment  with Ofatumumab in combination with etoposide and high- 
dose ara-C (OVA)  and subsequent  autologous stem  cell transplantation.  
3.3.3  To measure the effect  of OVA on other  clinically  meaningful  endpoints  including  OS, time to 
progression or relapse (TTP),  EFS, CR/PR proportion  at day +90.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  10  
  
 
3.3.4  To measure the FDG -PET conversion rate from PR to CR following  OVA and correlate  post-OVA  
PET results  with PFS,  TTP,  OS. 
3.3.5  To examine potential  relationships  between Ofatumumab  concentration at selected time points  and 
PFS,  TTP,  OS. 
3.3.6  To study  the safety  and tolerability  of OVA including:  infusion -related reactions,  B-cell number,  
hypogammaglobulinemia,  and long- term hematologic  toxicity.  
3.3.7  To store tumor  tissue for future molecular  subtyping.  
3.3.8  To evaluate minimal -residual  disease testing in  the setting of  transplantation.  
 
 
 

Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  11  
  
 
4 Subject  Selection  and Withdrawal  
4.1 Inclusion  Criteria  
Patients  fulfilling  ALL of the following criteria  are eligible for entry to the study:  
 
4.1.1  Diagnosis  of refractory  or relapsed  biopsy -proven CD20+  diffuse  large B- cell lymphoma or primary  
mediastinal  B-cell lymphoma.  
 
4.1.2  Age 18 years  or older  
 
4.1.3  Refractory  to or relapse following  a rituximab/anthracycline first-line regimen 
 
4.1.4  High-risk disease as  defined  by one of  the following:  
• First relapse after CR within 12 months  of initiation of front -line therapy  
• Less than CR  to front -line therapy  
• sAAIPI  of 2 or higher at the time of relapse (see attachment 14.2)  
 
4.1.5  Receipt  of no more than three prior chemotherapy  regimens.  Monoclonal  antibody  therapy  alone 
and involved field radiotherapy  are not included in this number.  Prior  use of ofatumumab  is allowed if 
there has been no disease  progression following  that therapy  (i.e. ofatumumab -based salvage regimens  
are allowed)  
 
4.1.6  ECOG  performance status  ≤ 2. 
 
4.1.7  Patient  must  be consented to the study  prior to salvage  assessment  
 
Eligibility  to proceed  to OVA  
a. Chemosensitive  disease as defined by at least  a partial  response  to salvage therapy  by 
PET/CT  criteria.  
b. Bone marrow  with less than 15% lymphoma cells following  salvage therapy.  No evidence 
of myelodysplasia.  
c. Patients  must  have adequate organ function with serum  creatinine <2.0 mg/dL,  total 
bilirubin  ≤2X ULN,  and AST ≤3X ULN.  
d. Neutrophils  >1,000/μL and platelets  >100,000/μL prior to day 0 
e. No active  uncontrolled infection.  
 
 
4.2 Exclusion  Criteria  
Patients fulfilling  ANY of the following criteria  are NOT eligible for entry  to the study:  
 
4.2.1  Presence of  disease transformation from  a previously  diagnosed low-grade lymphoma. 
 
4.2.2  Progression following  prior ofatumumab- based therapy . 
 
4.2.3  Active  central  nervous  system  or meningeal  involvement  by lymphoma.  Patients  with a history  of 
CNS  or meningeal  involvement  must  be in a documented  remission  by CSF evaluation and contrast  MRI 
imaging for at least 3 months  prior to study  entry.  
 
4.2.4  Evidence of myelodysplasia on any bone marrow  biopsy.  
 
4.2.5  Treatment  with any known non-marketed  drug substance or experimental  therapy  within  5 terminal  
half-lives or 4 weeks  prior to enrollment,  whichever  is longer,  or currently  participating in any other  
interventional  clinical study.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  12  
  
 
4.2.6  Other  past or current  malignancy.  Subjects  who have been free of malignancy  for at least  3 years,  
or have a history  of completely  resected non-melanoma skin cancer,  or successfully  treated in situ 
carcinoma are  eligible.  
 
4.2.7  Chronic  or current  infectious  disease requiring systemic  antibiotics,  antifungal,  or antiviral  treatment  
such as,  but not limited  to, chronic renal  infection,  chronic chest  infection  with bronchiectasis,  tuberculosis  
and active  Hepatitis  C. 
 
4.2.8  History of  significant  cerebrovascular  disease in  the past  6 months  or ongoing event  with active  
symptoms  or sequelae. 
4.2.9  Known HIV infection . 
4.2.10  Clinically  significant  cardiac  disease including  unstable angina,  acute myocardial infarction  within  
six months  prior to randomization, congestive heart  failure (NYHA  III-IV), and arrhythmia unless controlled 
by therapy,  with the exception of  extra systoles  or minor  conduction abnormalities.  
4.2.11  Significant  concurrent,  uncontrolled medical  condition including, but  not limited  to, renal,  hepatic,  
gastrointestinal,  endocrine,  pulmonary,  neurological,  cerebral  or psychiatric  disease which  in the opinion 
of the investigator may represent  a risk for the patient.  
4.2.12  Positive  serology  for Hepatitis  B (HB) defined as a positive  test for HbsAg  and a detectable  HBV 
DNA  viral load.  If negative for HBsAg  but HBcAb  positive  (regardless  of HBsAb  status),  a HBV DNA  test 
will be performed and if positive  the subject  will be excluded.  If HBV DNA  is negative,  subject  may be 
included but must  undergo  at least  every  2-month  HBV DNA  PCR  testing from the start of treatment  
during the treatment  course.  Prophylactic  antiviral  therapy  may be initiated  at the discretion of the 
investigator.  
 
4.2.13  Positive  serology  for hepatitis  C (HC)  defined as  a positive  test for  HCAb, in  which case  reflexively  
perform a HCV  PCR  to confirm  the result . 
4.2.14  Pregnant or  lactating women.  Women of  childbearing potential  must  have a negative pregnancy  
test at screening.  
4.2.15  Women of  childbearing potential,  including women  whose  last menstrual  period was  less than one 
year prior to screening,  unable or unwilling  to us e adequate contraception from study  start to one year 
after the last dose  of protocol  therapy.  Adequate contraception is defined as  hormonal birth control,  
intrauterine device,  double barrier  method or  total abstinence.  
4.2.16  Male subjects  unable or unwilling  to use adequate contraception  methods  from study  start to one 
year after the last dose of  protocol therapy.  
 
4.2.17  Subjects  who have received  live virus  vaccination  within  the 4 weeks  prior to planned initiation  of 
study  treatment.  
 
4.3 Subject  Recruitment  and Screening  
Patients  will be identified  by the principal  investigator  and sub-investigators  in the malignant  
hematology/BMT  clinic  at UCSF  and be registered on this study.  Subjects  can enter  the study  any time 
after a documented relapse.  
 
4.4 Early  Withdrawal  of Subjects  
UCSF retains  the right  to terminate the study  at any time.  
UCSF  retains  the right to terminate an individual  study  patient’s  participation in the study  due to the 
following:  
1. Noncompliance with study  procedures  
2. Concomitant use  of any study  drug or  procedure without prior  approval  from the Principal  Investigator  
3. Unanticipated adverse medical  experiences  in this or other  studies  indicating a potential  health hazard 
caused by  the study  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  13  
  
 
4. Study  patient’s  withdrawal  from protocol  
5. No evidence of response (PR or CR) to salvage therapy.   Subjects  will be allowed to proceed to a 
different  salvage regimen and will be re-evaluated following this. If still without  a PR or CR, they will be 
withdrawn for  this reason and replaced.  
 
4.5 Data  Collection  and Follow -up for Withdrawn Subjects  
If a subject  withdraws  consent  to participate in the study  prior to day 0 of OVA,  he or she will be replaced.  
If a subject  withdraws  consent  on day 0 of OVA or later,  attempts  will be made to obtain permission to 
record at least  survival  data up to the protocol -described end of subject  follow -up period qt 24 months.  
For the latter  subjects,  we will continue  to record  disease -specific  data,  adhering  to the protocol  as much  
as possible.  This data will be obtained  (with  the subject’s  permission)  from local treating physicians  if the 
subject  is no longer followed at UCSF.  
 
 
5   On Study Evaluation  
5.1 Registration  
 
5.1.1  History  including demographics,  detailed description  of prior anti-lymphoma  therapy,  
complications  associated with therapy  (i.e. infections,  liver toxicity)  and any ongoing medical  
problems.  Complete medication list. Complete physical  examination including  vital signs  and 
ECOG  performance status.  
 
5.1.2  Laboratory  studies:  
a. Hematology:  CBC,  differential,  platelets.  
b. Chemist ries:  Bilirubin,  AST,  ALT,  alkaline phosphatase,  creatinine, electrolytes,  LDH,  
glucose,  albumin,  total protein.  
c. PT/PTT 
d. Serum  Pregnancy  Testing 
e. Serologies:  HBsAb,  HBcAb,  HbsAg,  HCAb.  
f. Subjects  who are HBcAb  positive  must  undergo HBV DNA  PCR  testing.  
 
5.1.3  20 unstained slides  or tissue  block  from the time of relapse (preferred)  or initial diagnosis,  if either  
available,  will be acquired.  Ten slides  will be used for minimal- residual  disease (MRD)  test 
calibration and the rest  will be stored for future DLBCL subtyping.  
 
5.1.4  10 cc of peripheral  blood for  baseline MRD  testing  
 
5.2 Salvage Response  Assessment  
TO BE COMPLETED  AFTER  SALVAGE THERAPY 
Salvage therapy  is standard treatment  for relapsed diffuse  large  cell lymphoma patients.  These  regimens  
can consist  of different  agents,  such  as R-ICE, R-DHAP,  R-Gem/Ox,  and others.  Salvage therapy  is done 
outside of this protocol ; however,  a response to salvage therapy  is required prior to proceeding with OVA  
therapy,  per eligibility  criteria.  
 
5.2.1  Interim  history,  concomitant  medications, and complete  physical  examination including  vital signs.  
 
5.2.2  Laboratory  studies:  
a. Hematology:  CBC,  differential,  platelets.  
b. Chemist ries:  Bilirubin,  AST,  ALT,  alkaline phosphatase,  creatinine, electrolytes,  LDH,  
glucose,  albumin,  total protein.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  14  
  
 
5.2.3  Bone marrow  aspirate  and biopsy  within  8 weeks  of the end of salvage therapy,  and before the 
start of OVA.  This should include morphology  and standard cytogenetics.  Required to proceed to 
OVA.  
 
5.2.4  Lumbar  puncture  with cell count,  differential  and protein  within  8 weeks  IF patient  has had prior 
CNS involvement  or has suspicion  of CNS  disease.  
 
5.2.5  FDG -PET and CT Neck,  Chest,  Abdomen,  Pelvis  with PO/IV  contrast  or PET/CT  within  4 weeks  
from initiation  of last  cycle  of salvage therapy.  
 
5.2.6  12-lead EKG  
 
5.2.7  Cardiac  ejection  fraction  by Echo  or MUGA  within  8 weeks  of salvage response assessment.  
Required to proceed to transplant, but not to OVA.  
 
5.2.8  Pulmonary   function  testing  with  DLCO   within   8  weeks   of  salvage  response  assessment.  
Required to proceed to transplant, but not to OVA.  
 
5.2.9  10cc of  peripheral blood for MRD  testing.  Sendout.  
 
OVA STEP  
 
5.3 Day 0 of OVA  
OVA therapy  will begin  within 2 weeks  following  Salvage Response Assessment.  
 
5.3.1  Interim  history,  concomitant  medications, and complete  physical  examination including  vital signs.  
 
5.3.2  Laboratory  studies:  
a. Hematology:  CBC,  differential,  platelets.  
b. Chemist ries: Bilirubin,  AST,  ALT,  alkaline phosphatase,  creatinine,  electrolytes,  calculated 
creatinine  clearance,  glucose,  albumin,  uric acid,  LDH.  PT and Fibrinogen.  Quantitative IgG, IgA, 
IgM. 
c. Peripheral blood CD19+ B- cell determination by flow  cytometry.  
 
5.3.3  Ofatumumab  administration  (see section 6.1.1)  
 
5.4 All other  days  of OVA  
 
5.4.1  Laboratory studies  until completion of apheresis:  
Daily  CBC,  differential,  platelets,  electrolytes,  creatinine.  
Twice -weekly Bilirubin,  alkaline phosphatase,  AST,  ALT. 
 
5.4.2  Etoposide and Cytarabine administration on days  1-4 (see sections  6.1.2 – 6.1.4)  
 
5.4.3  Ofatumumab  administration  on days  7,14,21 (see section 6.1.1)  
 
5.4.4  GCSF  administration daily,  starting on day 14 and continued until stem cell  collection (see section 
6.1.5)  
 
5.4.5  Ofatumumab  pharmacokinetic  evaluation within 24 hours  after end  of infusion  on day  21 
 
5.4.6  4 PBMC  cryovials  will be stored at the time of first leukapheresis  for future  studies.   4 cc of 
apheresis product  on day  21 or later  will be used for MRD  testing.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  15  
  
 
5.5 Day 42 Evaluation (+/- 4 days)  
 
5.5.1  History  and complete physical examination including vital signs  and ECOG performance status.  
 
5.5.2  Laboratory  studies:  
a. Hematology:  CBC,  differential,  platelets.  
b. Chemist ries:  Bilirubin,  AST,  ALT,  alkaline phosphatase,  creatinine, electrolytes,  LDH,  
glucose,  albumin, and total protein,  and quantitative IgG, IgA,  IgM. 
c. Peripheral blood CD19+ B- cell determination by flow  cytometry.  
d. Ofatumumab  pharmacokinetic  evaluation  
e. Subjects  who are baseline HBcAb  positive  must  undergo HBV DNA  PCR  testing.  
 
5.5.3  Bone marrow  aspirate and biopsy  IF positive  for lymphoma at baseline.  This should include 
morphology  and standard cytogenetics.  
 
5.5.4  FDG -PET and CT Neck,  Chest,  Abdomen, Pelvis  with PO/IV  contrast  or PET/CT.  
 
5.5.5  10 cc of peripheral blood for MRD  testing.  
 
5.6 CBV  Administration 
 
Laboratory  studies:  
Daily  CBC,  differential,  platelets,  electrolytes,  glucose,  creatinine.  
Twice -weekly Bilirubin,  alkaline phosphatase,  AST,  ALT. 
 
TREATMENT  PER INSTITUTIONAL  STANDARD  OF CARE.   See Section 14.3 for UCSF  recommended 
Standard of Care.  
 
5.7 Day +30’ and +60’ Evaluation (+/- 4 days)  
 
5.7.1  History  and complete physical examination including vital signs  and ECOG performance status.  
 
5.7.2  Laboratory  studies:  
a. Hematology:  CBC,  differential,  platelets.  
b. Chemist ries:  Bilirubin,  AST,  ALT,  alkaline phosphatase,  creatinine, electrolytes,  LDH,  
glucose,  albumin,  and to tal protein.  
c. Subjects  who are baseline HBcAb  positive  must  undergo HBV DNA  PCR  testing.  
 
5.8 Day +90’ Evaluation (+/- 4 days)  
 
5.8.1  History  and complete physical examination including vital signs  and ECOG performance status.  
 
5.8.2  Laboratory  studies:  
a. Hematology:  CBC,  differential,  platelets.  
b. Chemisties:   Bilirubin,   AST,   ALT,   alkaline  phosphatase,   creatinine,  electrolytes,   LDH,  
glucose,  albumin, and total protein,  and quantitative IgG, IgA,  IgM. 
c. Peripheral blood CD19+ B- cell determination by flow  cytometry.  
d. Ofatumumab  pharmacokinetic  evaluation  
e. Subjects  who are baseline HBcAb  positive  must  undergo HBV DNA  PCR  testing.  
 
5.8.3  Bone marrow  aspirate and biopsy  within  2 weeks  IF positive  for lymphoma at baseline.  This 
should include morphology  and standard cytogenetics.  
 
5.8.4  FDG -PET and CT Neck,  Chest, Abdomen, Pelvis with PO/IV contrast  or PET/CT  within 2 weeks.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  16  
  
 
 
5.8.5  Pulmonary  Function Testing  with DLCO  within  2 weeks.  
 
5.8.6  10 cc of peripheral blood for MRD  testing.  
 
5.9 Month  6, 12, and 24 Evaluation  (+/- 4 weeks)  
 
5.9.1  History  and complete physical examination including vital signs  and ECOG performance status.  
 
5.9.2  Laboratory  studies:  
a. Hematology:  CBC,  differential,  platelets.  
b. Chemist ries:  Bilirubin,  AST,  ALT,  alkaline phosphatase,  creatinine, electrolytes,  LDH,  
glucose,  albumin, and total protein,  and quantitative IgG, IgA,  IgM. 
c. Peripheral blood CD19+ B- cell determination by flow  cytometry.  
d. Ofatumumab  pharmacokinetic  evaluation at 6 months  or time of relapse,  whichever  occurs  
earlier.  
e. Subjects  who are baseline HBcAb  posit ive must  undergo HBV DNA  PCR  testing at 
month 6. 
 
5.9.3  FDG -PET IF positive  on day+90’ will  be repeated  at month  6. 
 
5.9.4  CT Neck, Chest,  Abdomen,  Pelvis  with PO/IV  contrast  or PET/CT.  
 
5.9.5  10 cc of peripheral blood for MRD  testing.  
 
5.10 At Time  of Suspected Relapse/Progression  
 
5.10.1  History  and complete physical examination including vital signs  and ECOG performance status.  
 
5.10.2  Laboratory  studies:  
a. Hematology:  CBC,  differential,  platelets.  
b. Chemist ries:  Bilirubin,  AST,  ALT,  alkaline phosphatase,  creatinine, electrolytes,  LDH,  
glucose,  albumin,  and total  protein.  
 
5.10.3  FDG -PET and CT Neck,  Chest,  Abdomen, Pelvis  with PO/IV  contrast  or PET/CT.  
 
5.10.4  Bone marrow  aspirate and biopsy  IF indicated.  This should include morphology  and standard 
cytogenetics.  
 
5.10.5  Tumor  tissue  (20 unstained  slides  or tissue  block)  from biopsy  confirming  relapse,  if feasible,  will 
be acquired and stored for  future testing.  
 
5.10.6  10 cc of peripheral blood for MRD  testing.  
 
 
6 Follow -up Phase 
 
I. If a subject  has progressive disease prior to  day 0 of OVA, he/she will be replaced.  
II. If patients  progress  between day 0 of OVA and day -6 of CBV,  and the intent  is to proceed to an 
autologous  stem  cell transplant  in the future , they will be followed at regular  intervals  starting on 
day +90 as specified in the protocol  for post-transplant  follow -up (Sections 5.8,5.9,5.10).  
III. If patients  progress  between day 0 of OVA and day -6 of CBV and the intent  is not to proceed  
with transplant  or if they progress  any time after day -6 of CBV,  they will be followed for survival  
only every  3 months  for up to 2 years  or death,  whichever  occurs  sooner.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  17  
  
 
IV. Patients  who do not progress  in the first 24 months,  will be followed for disease status  and 
survival  every  6 months,  until 5 years.  
 
 
7 Treatment  Regimen  
7.1 Intensive Mobilization  Regimen  (OVA)  
 
7.1.1 Ofatumumab  Administration at 1000mg  IV on days  0,7,14,  and 21. 
 
Pre-medication before  each ofatumumab  infusion must  be given within 30 minutes  to 2 hours  
prior to the treatment:  
Table  1   Pre-medication Requirements  prior  to Ofatumumab Infusions  
 
Infusion  
# Acetaminophen  
(po) 
or equivalent  Antihistamine  (iv 
or po) 
diphenhydramine 
or equivalent  Glucocorticoid  
(iv) 
prednisolone  
or equivalent  
1st 1000  mg 50 mg 50 mg 
2nd 1000  mg 50 mg 50 mg 
3rd and 
4th 1000 mg 50 mg 0 – 50 mg1 
If the 2nd infusion  has been  completed without  the subject  experiencing any grade = 3 AEs,  pre- 
medication with glucocorticoid may be reduced  or omitted  before  the 3rd or 4th infusion  at the 
discretion of the investigator.  
 
First  Infusion  of 1000 mg Ofatumumab,  day 0 
The initial rate of the first infusion  of 1000 mg ofatumumab  (1 mg/mL)  should be 12 mL/h.  If no 
infusion  reactions  occur  the infusion  rate should be increased every  30 minutes,  to a maximum of 
400 mL/h,  according  to Table 2. If this schedule  is followed,  the infusion duration  will be 
approximately  4.6 hours.  
 
Table  2: Infusion rate  at 1st ofatumumab infusion (1000 mg) 
 
Time  mL/hour  
0 – 30 minutes  12 
31 – 60 minutes  25 
61 – 90 minutes  50 
91 – 120 minutes  100 
121 - 150 minutes  200 
151 - 180 minutes  300 
181+  minutes  400 
 
If an infusion  reaction develops,  the infusion  should be temporarily  slowed  or interrupted.  Upon 
restart,  the infusion  rate should be half of the infusion  rate at the time the infusion was paused.  If, 
however,  the infusion  rate was 12 mL/hour  before the pause,  the infusion  should  be restarted at 
12 mL/hour.  Thereafter,  the infusion  rate may be increased according  to the judgment  of the 
investigator,  in the manner  described in  this section.  
 
 
Subsequent Infusions  of 1000 mg Ofatumumab,  days  7,14,  and 21 
If the previous  infusion  has been completed without  grade ≥ 3 infusion- associated AEs,  the 
subsequent  infusion  of the 1000 mg of ofatumumab  (1 mg/mL)  can start at a rate of 25 mL/hour  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  18  
  
 
and should be doubled every  30 minutes  up to a maximum  of 400 mL/h,  according to Table 3. 
Duration of the infusion  will be approximately  4 hours  if this schedule is followed.  If the previous  
infusion  has been completed with grade ≥ 3 infusion -associated AEs,  the subsequent  infusion  
should start at a rate of 12 mL/hour  according to Table 2.  
 
Table  3: Infusion rate at subsequent  ofatumumab infusions  
 
Time  mL/hour  
0 – 30 minutes  25 
31 – 60 minutes  50 
61 – 90 minutes  100 
91 – 120 minutes  200 
121+  minutes  400 
 
During infusion  the patient  should be monitored closely  and appropriate measurements  should be 
performed whenever  judged necessary.  
 
7.1.2  Etoposide  10 mg/kg  IV continuous  infusion  over  24 hrs for 4 days  (total  course dose  40 
mg/kg).  
 
Dose should be based on corrected weight,  calculated as follows:  Ideal  + 25% of the difference 
between actual  and ideal  weight.  If actual  is less than ideal  weight,  use actual  weight.  
 
Etoposide infusion  should be mixed  in normal  saline  at a concentration of 0.4-0.5 mg/ml.  The 
infusion  volume will be approximately  1.39 ml/kg/hour  and should be rounded to the nearest  500- 
1000 ml and infused  through  a central  venous  catheter.  
 
7.1.3  Cytarabine (ara-C) 2,000 mg/m2 IV over 2 h q 12 h x 8 doses Days 1- 4. 
 
Cytarabine dosage should  be based on corrected weight,  calculated as follows:  Ideal  weight  + 
25% of the difference  between actual  and ideal  weight.  If actual  weight  is less than ideal  weight,  
use actual  weight.  
 
Begin first cytarabine infusion at the end of first hour of etoposide.  Cytarabine doses  should be 
mixed  in 250 ml of D5W. 
 
7.1.4  To prevent  neurotoxicity  from high-dose  cytarabine (HDAC),  cytarabine doses  will be adjusted 
according to renal  function.  
 
 The dose  of cytarabine will be reduced  to 1000  mg/m2/dose  if creatinine  is 1.5-1.9 mg/dL 
or if there is an increase from baseline creatinine at start of cytarabine of 0.6-1.1 mg/dL 
(example:  baseline creatinine 0.8 mg/dL increase to 1.4 mg/dL (difference of 0.6 mg/dL)),  
decrease cytarabine to 1000 mg/m2/dose.  
 The dose  of cytarabine  will be reduced  to 100 mg/m2/day by continuous  infusion  if 
creatinine  > 2.0 mg/dL or if there  is an increase  from baseline  > 1.2 mg/dL and 4 or fewer  
cytarabine doses  have been administered.  The infusion  will end at the completion of the 96- 
hour etoposide infusion.  If 5 or more cytarabine doses  have been administered,  then 
discontinue  cytarabine.  
 If cytarabine neurotoxicity  develops  or is suspected (dysmetria,  dysdiadochokinesis,  
truncal/gait  ataxia,  dysarthria,  and/or  cerebral/psychiatric  abnormalities  not explainable by 
other  medications),  stop  cytarabine immediately. If 4 or fewer  of 8 planned high- dose  
cytarabine doses  have  been delivered,  cytarabine should be changed to 100 mg/m2/day  as 
continuous  IV infusion to end at the conclusion of the 96-hour etoposide infusion.  If 5 or more  
high- dose cytarabine doses  have been delivered,  then give no more cytarabine.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  19  
  
 
 
7.1.5  Supportive Care Measures:  
 
 G-CSF 10 mcg/kg  (actual  body  weight)  SQ daily beginning day 14 and should be continued  
until the peripheral  blood stem  cell collection has been completed.  Do not skip or dose  
reduce for bone  pain.  All G- CSF doses  should be rounded up to a convenient  dose based 
on vial sizes  of 300 mcg and 480mcg.  
 Fluoromethalone  0.1%  ophthalmic  solution  (or equivalent  medication)  2 drops  qid to each  
eye Days  1-6. 
 Voriconazole  4 mg/Kg  (corrected  weight)  rounded to the nearest  50 mg will be administered 
PO Q12 hours  beginning the day after completion of chemotherapy  (Day  6). Dose may be 
modified or omitted  due to toxicity  and equivalent  anti-fungal  prophylaxis  with fluconazole,  
itraconazole,  posaconazole or Liposomal -based amphotericin (1mg/kg)  may be used instead.  
 Prophylaxis  against  bacterial  infections  should begin when the ANC  is < 500/uL and continue 
until the ANC  is > 1000/uL.  Moxifloxacin  400 mg daily or an equivalent  antibiotic  is 
appropriate.  
 Acyclovir  400 mg PO bid or valcyclovir  500 mg PO qd beginning day 6. Continuing antiviral  
prophylaxis  following  hospital  discharge is recommended.  Patients  unable  to take oral 
medication should  receive  acyclovir  2 mg/kg IV q12 h.  
 Trimethoprim/Sulfamethoxazole  DS PO bid (or IV equivalent  dose)  every  Saturday  and 
Sunday  as Pneumocystis  carinii  prophylaxis.  For sulfa  allergy,  substitute Dapsone 100mg PO 
once every  Monday -Wednesday -Friday.  If intolerant  to dapsone,  substitute  aerosolized  
Pentamidine 300 mg Q month.  
 Patients  should be hospitalized in  private rooms  when possible.  
 Showers  are strongly  encouraged twice a day during days 1 to 6 to minimize  skin toxicity.  
 Strict low bacteria diet should be used when ANC  < 500 cells/uL.  
 Recommended mouth care:  salt and soda swish  tid 
 Transfusions : Institution standards  should be followed  for blood  product  support.  In lieu of 
standards,  packed RBCes  should be  given  to maintain the hemoglobin > 8.5 gm/dl  or hematocrit  
>25%.  Platelet  should  be transfused to keep the platelet  count  >10-20 x 109/l.  Blood  should be 
filtered  and irradiated (3000 cGy).  
 
7.2 PERIPHERAL  BLOOD  STEM  CELL  (PBSC)  COLLECTION  
 
7.2.1  Begin collections  when the total white  blood count  exceeds  10,000/µl  or when appropriate based  
on peripheral  CD34+  cell counts  (institutional  standard)  
7.2.2  Aim for a minimum  CD34  cell dose  of > 2 x 10 x 106/kg (actual  body  weight)  and an optimal  
target  CD34  cell dose  of > 5 x 106/kg (actual  body  weight).  
7.2.3  Stem  Cell Collection:  Process  18-20 L of whole blood over 3-4 hours  according  to institutional  
standards.  
7.2.4  PBSC  Processing:  The buffy  coat is concentrated by centrifugation.  Cells  are suspended  in 
Normosol  media with 5% autologous  plasma  and 10% DMSO  to a final cell concentration of 2.5 x 
108/ml. Seventy  ml aliquots  are placed in polyolefin bags  and frozen in a controlled rate freezer.  
Bags  are labeled then stored in the liquid  phase  of a liquid  nitrogen freezer.  Institutional  standard  
for PBSC  processing should be followed.  
7.2.5  Four 2 ml aliquots  of PBSC  will be frozen in liquid  nitrogen for future  analysis.  4 mL of PBSC  will 
be used for  MRD  testing,  if baseline test  was informative.  
7.2.6  Increased GCSF  dosing or plerixafor  (Mozobil)  supplementation may be utilized  after consultation  
with the principal  investigator  to augment  CD34+  cell yield.  Use of plerixafor  constitutes  a failure  
of mobilization  with OVA.  
7.2.7  Failure  to Colle c t Peripheral  Blood  Stem  Cells . Should the minimum number  of CD34  cells not 
be reached,  remobilization of peripheral  blood stem  cells or pelvic  bone marrow  harvest  is 
permitted.  The study  PI needs  to be consulted  regarding re-mobilization or bone marrow  harvest  
and the PI needs to grant permission for this  to proceed.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  20  
  
 
7.3 High -Dose  Therapy with Stem  Cell Rescue  (CBV)  
 
Drug administration and supportive care performed per  institutional  standard.  
 
7.4 Optional  Radiotherapy  
Radiation therapy  of a single site of residual disease or progression is  allowed following  OVA before or 
after transplant  at the investigator’s discretion.  
 
 
8 Measurement  of Effect  
8.1 Definition  of Adequate  Stem  Cell Collection  
Acceptable stem  cell collection  is defined as a minimum  CD34  cell dose  of > 2 x 10 x 106/kg 
(actual  body  weight)  and optimal  stem  cell collection  as a CD34  cell dose  of > 5 x 106/kg 
(actual  body  weight).  Use of plerixafor  or an autologous  bone marrow  harvest  are considered  
mobilization failures.  
 
8.2 Definition  of Engraftment  
Neutrophil  engraftment  is defined as the first day of 3 consecutive  days  with absolute neutrophil  
count  of >500 cells/uL.  Platelet  engraftment  will be defined as the first of three  consecutive 
measurements  for which  the platelet  count  was > 20,000/uL,  and must  be at least  24 hours  
following  the last  platelet  transfusion.  
 
8.3 Lymphoma  response  assessment  (revised  IWG criteria  [12])  
 
PET or PET/CT  scans  acquired  prior to study  entry  will be utilized  in evaluating the response to 
salvage  therapy  and the day 42 assessment.  Semi -quantitative and qualitative PET analysis  will 
be performed at our center  using SUV,  mediastinal  blood pool,  and liver uptake.  We recommend  
that all PET scans  be performed at the same  instrument at our institution.  
 
CR: The designation of CR requires  the following:  
 
1. Complete  disappearance of all detectable clinical evidence of disease and disease- related  
symptoms  if present  before therapy.  
2. A post-treatment  residual  mass  of any  size is permitted as  long as  it is PET  negative.  
3. The spleen and/or  liver,  if enlarged before therapy  on the basis  of the physical  examination  or 
CT scan,  should not be palpable on physical  examination and should be considered normal  size 
by imaging  studies,  and nodules  related to lymphoma should disappear.  However,  determination  
of splenic  involvement  is not always  reliable  because  a spleen considered normal  in size may still 
contain lymphoma,  whereas  an enlarged spleen may reflect  variations  in anatomy,  blood volume,  
the use of hematopoietic growth factors,  or causes  other than lymphoma.  
4. If the bone marrow  was involved by lymphoma before treatment,  the infiltrate  must  have 
cleared on repeat  bone marrow  biopsy.  The biopsy  sample on which  this determination  is made 
must  be adequate (with  a goal of > 20 mm unilateral  core).  If the sample  is indeterminate by 
morphology,  it should  be negative by immunohistochemistry.  A sample that is negative by 
immunohistochemistry  but that demonstrates  a small population of clonal  lymphocytes  by flow 
cytometry  will be considered a CR. 
 
PR: The designation of PR requires  all of the following:  
 
1) The post -treatment PET should be positive in at least  one previously involved site. 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  21  
  
 
2) At least  a 50% decrease  in sum of the product  of the diameters  (SPD)  of up to six of the 
largest  dominant  nodes  or nodal  masses.  These nodes  or masses  should be selected according  
to all of the following:  they should be clearly  measurable  in at least  2 perpendicular  dimensions;  if 
possible they should be from disparate regions  of the body;  and they should  include mediastinal  
and retroperitoneal  areas  of disease whenever these sites are involved.  
3) No increase should be observed in  the size  of other  nodes,  liver, or spleen.  
4) Splenic  and hepatic  nodules  must  regress by  ≥ 50% in their SPD or, for single  nodules,  in 
the greatest  transverse  diameter.  
5) With the exception of splenic  and hepatic  nodules,  involvement  of other  organs  is usually  
assessable and no measurable disease should be present.  
6) Bone marrow  assessment  is irrelevant  for determination of a PR if the sample was 
positive  before  treatment.  However,  if positive,  the cell type should be specified  (eg, large- cell 
lymphoma or small neoplastic  B cells).  Patients  who achieve a CR by the above criteria,  but who 
have persistent  morphologic  bone marrow  involvement  will be considered partial  responders.  
When  the bone marrow  was involved before  therapy  and a clinical CR was achieved,  but with no 
bone marrow  assessment after  treatment,  patients should be considered  partial responders.  
7) No new  sites of dis ease should be observed.  
 
Stable Disease : Stable disease (SD) is defined as  the following:  
1) A patient  is considered  to have  SD when he or she fails to attain the criteria  needed for a 
CR or PR, but does  not fulfill those  for progressive  disease (see Relapsed Disease  [after  
CR]/Progressive  Disease  [after  PR, SD]). 
2) The PET should be positive  at prior sites of disease with no new areas  of involvement  on 
the post-treatment CT or PET.  
 
Relapsed  Disease (after  CR)/Progressive Disease (after  PR, SD):  
Lymph  nodes  should  be considered abnormal  if the long axis is more  than 1.5 cm regardless  of 
the short  axis. If a lymph  node has a long axis of 1.1 to 1.5 cm, it should only be considered  
abnormal  if its short  axis is more than 1.0. Lymph nodes  ≤ 1.0 x ≤ 1.0 cm will not be considered  
as abnormal  for relapse or  progressive disease.  
1) Appearance of any new lesion  more  than 1.5 cm in any axis during or at the end of 
therapy,  even if other  lesions  are decreasing in size. Increased FDG  uptake  in a previously  
unaffected site should only be considered relapsed or progressive disease after confirmation with 
other  modalities.  
2) At least  a 50% increase from nadir  in the SPD of any previously  involved nodes,  or in a 
single involved node,  or the size of other  lesions  (eg, splenic  or hepatic  nodules).  To be 
considered progressive disease,  a lymph  node with a diameter  of the short  axis of less than 1.0 
cm must  increase by  ≥ 50% and to a size of 1.5 x 1.5 cm or more than 1.5 cm in the long axis.  
3) At least  a 50% increase in the longest  diameter  of any single  previously  identified node 
more than 1 cm in its short  axis. 
4) Lesions  shoul d  be PET positive  unless  the lesion  is too small to be detected with current  
PET systems (< 1.5 cm in its long  axis by CT).  
Measurable extranodal  disease should be assessed  in a manner  similar  to that for nodal  disease.  
For these  recommendations,  the spleen is considered nodal  disease.  Disease  that is only 
assessable (eg, pleural  effusions,  bone lesions)  will be recorded as present  or absent  only,  
unless,  while  an abnormality  is still noted by imaging studies  or physical  examination,  it is found  
to be histologically  negative.  
 
8.4 Survival -time parameters  
 
 Overall  Survival  is defined  as the time from day 0 until death as a result  of any cause.  
Patients  will be censored at the time of  last followup.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  22  
  
 
 PFS is defined as the time from day 0 until lymphoma progression,  receipt  of anti-lymphoma  
therapy  (except  for planned post-ASCT  radiotherapy),  or death  as a result  of any cause.  
Patients  will be censored at the time of  last followup.  
 
 Time  to Progression : Time  to progression (TTP)  is defined  as the time from study  entry  until 
documented lymphoma progression  or receipt  of anti-lymphoma therapy  (except  for planned  
post-ASCT  radiotherapy)  or death due to lymphoma.  Patients  are to be censored at the time 
of last  followup or  death due to another cause.  
 
 Event- Free  Survival : Event -free survival  (time  to treatment  failure)  is measured from day 0 
to any treatment  failure  including  disease progression,  discontinuation of treatment  for any 
reason,  initiation  of new therapy  without  documented  progression,  incidence of secondary  
AML or MDS,  or death related  to treatment.  Patients  are censored at the time of last followup 
or death unrelated to treatment  or disease.  
 
 
9 Safety and  Adverse Events 
9.1 Safety  Definitions  
 
9.1.1  Adverse Events:  
Any untoward medical  occurrence  in a subject  or clinical investigation subject,  temporally  associated with 
the use of  a medicinal  product,  whether  or not considered related to the medicinal  product.  
Events meeting the definition of an AE include:  
• Any abnormal laboratory test  results  (hematology,  clinical chemistry,  or urinalysis) or  other safety  
assessments  e.g., ECGs, radiological  scans,  vital signs  measurements),  including those that  worsen 
from baseline,  and felt  to be clinically  significant  in the medial  and scientific  judgment  of the 
investigator  
• Exacerbation of  a chronic  or intermittent  pre-existing condition including either  an increase in  
frequency  and/or  intensity  of the  condition  
• New conditions  detected or  diagnosed after investigational  product  administration even though it  
may have been present  prior to the start of the study  
• Signs,  symptoms,  or the clinical  sequelae of a suspected interaction  
• Signs, symptoms,  or the clinical  sequelae of a suspected overdose of either investigational product  
or a concomitant  medication (overdose per se will not be reported as an AE/SAE)  
“Lack  of efficacy”  or “failure  of expected pharmacological  action”  per se will not be reported  as an AE or 
SAE.  However,  the signs  and symptoms  and/or  clinical sequelae resulting from lack of efficacy  will be 
reported  if they fulfill the definition of an AE or SAE.  
 
  
 
Events that  do not meet  the definition of an AE  include:  
• Any clinically  significant  abnormal laboratory finding or other abnormal  safety  assessments that  is 
associated with the underlying disease,  unless  judged by the investigator to be more severe than 
expected for the subject’s  condition.  
• The disease/disorder  being studied,  or expected progression, signs,  or symptoms  of the 
disease/disorder being studied,  unless  more severe than expected for the subject’ s condition  
• Medical  or surgical  procedure (e.g.,  endoscopy, appendectomy); the condition that leads to the 
procedure is an AE  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  23  
  
 
• Situations  where an untoward medical  occurrence  did not occur  (social  and/or  convenience 
admission to a hospital)  
• Anticipated day -to-day fluctuations  of pre- existing disease(s)  or condition(s)  present  or detected at  
the start of the study  that do not worsen  
• B cell depletion and hypogammaglobulinemia due to ofatumumab  treatment  
 
9.1.2  Grading: AEs and toxicities  will be graded  using  the NCI Common Toxicity  Grading Scale  
(Version 4.0; http://ctep.cancer.gov/reporting/ctc.html)  included in Appendix  1. AEs that are not included  
in the NCI  Common Toxicity  Criteria  will be graded as follows:  
 
1. Mild (Grade 1) – near the lowest  intensity  (or within  the lower  one-third)  typically  seen with the 
observed sign or symptom  
2. Moderate  (Grade 2)  – average intensity  typically  seen with the observed sign  or symptom  
3. Severe  (Grade 3) – near the highest  intensity  (or within  the top third)  typically  seen with the observed 
sign or symptom  
4. Life-threatening (Grade 4) – any AE that places  the patient,  in the view of the investigator,  at 
immediate risk of death from the reaction as it occurred.  It does  not refer to an event  that hypothetically  
might  have caused death if  it were  more severe.  
5. Fatal  (Grade 5) 
 
 
9.1.3  Causality:  The association  or relationship of the AEs to targeted busulfan  will be defined  
according to the NCI  Common Toxicity  Criteria  guidelines  as follows:  
1. Definite  – The AE is clearly  related to the study  product,  e.g., an event  that follows  a reasonable  
temporal  sequence from administration of the drug or in which  the drug level has been established  in 
body  fluids  or tissues,  that follows  a known or expected  response pattern to the suspected drug,  and that 
is confirmed by  improvement  on stopping or reducing the dosage of  drug 
2. Probable  – The AE is likely  related to the study  product,  e.g., an event  that follows  a reasonable  
temporal  sequence from administration of the drug,  that follows  a known or expected response pattern to 
the suspected drug,  that is confirmed by stopping or reducing the dosage of the drug,  and that could be 
reasonably  explained by  the known characteristics  of the subject’s  clinical state  
3. Possible – The AE may be related to the study  product,  e.g., an event  that follows  a reasonable 
temporal  sequence from administration of the drug,  that follows  a known or expected response pattern to 
the suspected drug, but  that could readily  have been produced by a number of other  factors  
4. Unlikely  – The AE is doubtfully  related to the study  product  
5. Unrelated – The AE  is clearly  not related  to the study  product  
6. Not applicable – The AE occurred prior  to administration of  the study  product  
7. Unknown  – No evaluation for  causality  can be made 
 
9.1.4  Definition of a SAE 
A serious  adverse event is  any untoward medical  occurrence that,  at any  dose:  
a. Results  in death  
b. Is life-threatening  
NOTE:  The term 'life-threatening'  in the definition of 'serious'  refers  to an  event in which the subject  
was at  risk of death at  the time of the  event.  It does  not refer  to an  event,  which hypothetically  might  
have caused death,  if it were  more severe.  
c. Requires hospitalization or prolongation  of existing  hospitalization  
NOTE:  In general, hospitalization signifies  that the subject  has been detained (usually  involving at  
least an overnight stay)  at the hospital or emergency ward for observation and/or treatment  that 
would not  have been appropriate in the  physician’s  office or  out-patient  setting.  Complications  that 
occur during hospitalization are AEs.  If a complication  prolongs hospitalization or fulfills  any other  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  24  
  
 
serious  criteria,  the event  is serious.  When in  doubt  as to whether  “hospitalization” occurred or was  
necessary, the AE should be considered serious.  
Hospitalization for elective treatment  of a pre-existing  condition that did not  worsen from  baseline is  
not considered an AE.  
Hospitalizations or  procedures performed  for the routine  purpose of chemotherapy  administration will 
not be collected  as adverse  events  and will not be reported as  serious  adverse events.  This would 
include any  elective hospitalization for the administration of  radiation and/or  chemotherapy,  or 
hospitalization for the placement of central  venous  catheters  to be used for  chemotherapy  
administration . 
d. Results  in disability/incapacity  
NOTE:  The term disability means  a substantial  disruption of a person’s ability to conduct  normal  life 
functions.  This definition  is not intended to include  experiences  of relatively  minor  medical  
significance such  as uncomplicated headache,  nausea,  vomiting,  diarrhea,  influenza,  and accidental  
trauma (e.g.  sprained ankle) which may interfere or prevent  everyday  life functions  but do not  
constitute a substantial  disruption.  
e. Is a congenital  anomaly/birth defect  
f. Medical  or scientific  judgment  should be exercised in  deciding whether  reporting is  appropriate in  
other situations,  such  as important medical  events  that may not be immediately  life threatening or 
result  in death or  hospitalization but  may jeopardize the subject  or may require medical  or surgical  
intervention to prevent  one of the other  outcomes  listed  in the above definition.   These should als o 
be considered serious.  Examples  of such  events  are invasive  or malignant  cancers,  intensive 
treatment  in an emergency room  or at home for allergic bronchospasm,  blood dyscrasias or 
convulsions  that do not  result  in hospitalization,  or development of  drug dependency or  drug abuse.  
 
 
9.1.5  Labo
ratory  and Other  Safety  Assessment  Abnormalities  Reported  as AEs  and SAEs  
• Any abnormal laboratory test  results  (hematology,  clinical chemistry,  or urinalysis) or  other safety  
assessments  (e.g.,  ECGs,  radiological  scans,  vital signs  measurements),  including  those that  
worsen from baseline,  and felt to be clinically  significant  in the medical  and scientific  judgment of  
the investigator are to be recorded as AEs or SAEs.  
 
• All events meeting liver stopping criteria  must  be recorded as an SAE.  
 
• However, any clinically  significant  safety  assessments that are associated with the underlying 
disease, unless  judged by the investigator  to be more  severe  than expected for the subject’s  
condition,  are not to be reported as AEs  or SAE s. 
 
• B cell depletion,  IgG below  LLN, low  CD19+ count,  and hypogammaglobulinemia due to  
treatment with ofatumumab are not to be reported as AEs or SAEs.  
 
• Infusion related AEs may lead to a prolonged infusion time. Overnight  stay at the hospital due to  
slow infusion rate is not to be reported as a SAE.  
  
9.1.6  Disease- Related  Events  and/or  Disease -Related  Outcomes Not  Qualifying as  SAEs  
An event  which  is part of the natural  course of the disease under  study  (i.e., disease progression)  does  
not need to be reported as an SAE.  However,  if the progression of the underlying  disease is greater  than 
that which  would normally  be expected for the subject,  or if the investigator  considers  that there was a 
causal  relationship between treatment  with investigational  product  or protocol  design/procedures  and the 
disease progression, then this must  be reported as an SAE.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  25  
  
 
9.2 Time  Period  and Frequency  of Detecting  and Reporting SAEs  
Once  an investigator  determines  that an event  meets  the protocol  definition  of an SAE,  the SAE will be 
reported to NOVARTIS within  24 hours  of being notified of the event.  All SAEs  regardless  of relationship 
to investigational  product  will be collected  from the first dose of investigational  product  to after the last 
dose of  investigational  product (minimum of 6 months  or until the end of  the follow -up period which ever is 
longer). All SAEs  regardless  of causality  will be collected until the end of the  follow -up period.  
 
From  the time a subject  consents  to participate in and completes  the study  all SAEs  assessed  as related  
to study  participation  (e.g.,  protocol -mandated procedures,  invasive  tests,  or change in existing  
therapy)  or related  to NOVARTIS  concomitant  medication, will be reported promptly  to NOVARTIS.  
 
Any SAE brought  to the investigator’s  attention after the subject  has completed  the study  and considered  
by the investigator  as possibly  related  to investigational  product must  be reported to NOVARTIS.  
 
You should  report  safety  data to Novartis  by fax to:  
• U.S. Drug Safety  & Epidemiology   
o (Should the designated SAE Fax# be non-functional  please send SAEs  to the designated SAE 
mailbox:  clinicalsafetyop.phuseh@novartis.com)  
• The attached C oversheets must  be attached to all SAE submissions  
• SAE Submissions  must  reference your Novartis Study Code: COMB157DUS22T  
 
Reporting Process to UCSF  IRB 
Serious  and unexpected  adverse events should be reported to the UCSF IRB within 10 working days  of 
the occurrence.  This includes  any adverse experience which  is fatal or life-threatening,  permanently  
disabling,  requires  inpatient  hospitalization or  prolongs  hospitalization,  or has not been identified in  
nature,  severity  or frequency  in the literature.  Should a serious  or unexpected toxicity  occur  please 
contact:  
 
Pregnancy  
Any pregnancy  that occurs  during study  participation must be reported  to NOVARTIS.  To ensure  subject  
safety, each pregnancy  must  be reported to NOVARTIS within  2 weeks  of learning of its occurrence.  The 
pregnancy  must  be followed up to determine outcome (including  premature  termination)  and status  of 
mother  and child.  Pregnancy  complications  and elective  terminations  for medical  reasons  must  be 
reported as an AE or SAE.  Spontaneous  abortions must  be reported as an SAE.  
Any SAE occurring  in association with a pregnancy,  brought  to the investigator’s  attention after the 
subject  has completed the study  and considered  by the investigator  as possibly  related  to the 
investigational  product,  must  be promptly  reported to NOVARTIS.  
In addition,  the investigator  must  attempt  to collect  pregnancy  information on any female partners  of male  
study  subjects  who become pregnant  while  the subject  is enrolled in the study.  Pregnancy  information  
must  be reported to NOVARTIS as described  above.  
 
9.3 Special  Reporting Considerations  
 
9.3.1  Intensive Consolidation and Stem  Cell Mobilization  with OVA  
The following  adverse events  are expected,  based  on experience with Etoposide and High-Dose 
Cytarabine in this patient  population.  They  will be documented in the patient  medical  record but will 
ONLY be recorded in  the Case  Report  Form  if they are grade 3 -5. 
Neutropenia: expect ANC < 500/µL for  approximately 14 days with recovery  to >500/µL by day 28. 
Thrombocytopenia: expect  platelets  <20,000/µL for 10-14 days  with recovery  to >25,000/µL without  
transfusion  support  by day 28. 
Anemia: Expect  to transfuse approximately  6 units  of packed RBC.  
Stomatitis: most  patients  do not  need narcotic  analgesia or  TPN, but  both are possible.  

Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  26  
  
 
Diarrhea:  enterocolitis  is uncommonly  seen.  
Skin:  diffuse erythema is expected  and common  shortly  after chemotherapy.  Exfoliative  dermatitis  with 
blistering is uncommon. It would be unusual  to need >7 days of narcotic  analgesia for skin toxicity.  
Fatigue/Performance Status:  patients  require hospitalization for all or most  of OVA  and may be unable 
to fully care for themselves  for 1-2 weeks following hospitalization.  
 
9.3.2  High -Dose  Therapy  with CBV  and Stem  Cell Rescue 
The following  adverse  events  are expected,  based on experience with CBV in this patient  population.  
They  will be documented in the patient  medical  record but will ONLY  be recorded in the Case Report  
Form  if they are grade 3 -5. 
Neutropenia: absolute neutropenia is expected for 7 -10 days. Neutrophils begin to engraft around day +8 
to +10. Lack  of neutrophil  engraftment  by day +21 IS REPORTABLE.  
Thrombocytopenia:  Grade  4 thrombocytopenia is expected for 7-14 days.  Platelet  transfusion- 
independence usually  occurs  by day +9 to +12. Expect  approximately  3 platelet  transfusions.  Reportable 
platelet recovery  would be failure  to reach transfusion  independence by day +28. 
Anemia: expect  to transfuse  4-6 units  of packed RBC.  
Stomatitis: Grade 4 stomatitis  can occur  but is uncommon,  usually  between  day +3 to +10. Some  
patients  will require narcotic  analgesia and possibly  TPN (depending on institutional  practices).  
Diarrhea:  enterocolitis  is uncommon,  but may occur.  It generally  requires  narcotic  analgesia,  anaerobic  
antibiotics,  and TPN.  
Skin:  exfoliative  dermatitis  requiring local skin care (including blistering  and weeping wounds)  may occur  
and may require narcotic  analgesia;  palms  and soles  and intertriginous  areas  are most  common.  Skin 
breakdown > 2 weeks  would be considered distinctly  unusual.  
Fatigue  & Performance  Status: patients  will be hospitalized for most  or all of this therapy.  They  are 
unlikely to be able to fully  care for themselves  for 1-2 weeks post -hospital  discharge.  
 
 
10 Study Drug  and Chemotherapeutic  Agents  
10.1 Ofatumumab  (Arzerra)  
Pharmaceutical  Presentation 
Ofatumumab  is formulated at two strengths,  20 mg/mL  
and 100 mg/mL,  for IV and SC administration.  
 
Formulation Presentation  
20 mg/mL,  acetate buffer 100 mg/vial  (5 mL/vial)  
20 mg/mL  acetate buffer  1000 mg/vial  (50mL/vial)  
100 mg/mL,  acetate bu ffer 500 mg/vial  (5 mL/vial)  
100 mg/mL,  acetate buffer 100 mg/vial  (1 mL/vial)  
 
All drug product  presentations  are prepared aseptically  and filled into clear  glass,  stoppered  vials.  The 
products  are formulated without  a preservative  and are  supplied as  a single use vial.  
 
Physical,  Chemical  and Biological  Properties  of the Drug  Substance 
Approved Name:  INN: Ofatumumab 
Chemical   Name   (Chemical  Abstracts):   Immunoglobulin  G1,  anti-(human  CD20   (antigen))  (human 
monoclonal  HuMax -CD20 heavy chain),  disulfide with human monoclonal  HuMax -CD20 κ-chain, dimer  
(CAS number:  679818- 59-8) 
Other Names: Genmab Product  code:  HuMax -CD20  
Genmab Laboratory  Code:  2F2 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  27  
  
 
 
Biochemical  and Structural  Information:  Ofatumumab is  a  fully human immunoglobulin G1 antibody  
(IgG1- kappa)  against  human CD20  molecule expressed on B cells.  The antibody  consists of two heavy  
IgG1 chains  and two light kappa chains.  The heavy  chains  are connected to each  other  by two interchain 
disulfide bonds  and one light chain is attached to each  heavy  chain  by a single  interchain disulfide bond.  
The light chain has two intrachain disulfide  bonds  and the heavy  chain  has four intrachain  disulfide  bonds.  
The C- terminal  lysine  on the heavy  chain  is subject  to partial  post-translational  cleavage,  resulting  in 
antibody  populations  which  contain  0, 1, or 2 C- terminal  lysine  residues.  The majority  of the C- terminal  
heavy  chains  are clipped.  There is a single  N-linked  glycosylation site on each heavy  chain.  The major  
glycans present  are fucosylated  biantennary  structures  with varying  amounts  of terminal  galactose.  
Molecular Weight  149 kDa (including  carbohydrate residues  approximately  2%). 
Physical Form Clear,  colourless  liquid (at 20 mg/mL).  
Clear  to hazy, colourless  to pale yellow  liquid (at 100 mg/mL).  
 
Summary  of Manufacturing Process  and Quality  Assurance  
Ofatumumab  Injection  presentations  were  prepared  according to current  Good Manufacturing Practice  
(cGMP)  and tested according to International  Conference on Harmonization (ICH)  and Food and Drug  
Administration (FDA) Guidelines  for monoclonal  antibodies  and products  derived from recombinant  DNA  
technology.   The  cell  banks   used   to  manufacture  ofatumumab   have  been  extensively   tested  to 
demonstrate freedom  from adventitious  virus  contamination.  Ofatumumab  is produced by a recombinant  
mammalian  cell line, and no animal  derived raw materials  are used in the manufacture of Ofatumumab  
Injection.  The antibody  is purified by a multi- step sequential  chromatography  and filtration  process,  which  
has been validated to demonstrate removal  and inactivation of a range of  viruses  in compliance with  ICH 
guidelines.  
 
Storage and Handling  
The recommended storage conditions  and expiration date,  where required,  are stated on the product  
label  for Ofatumumab  Injection 20 mg/mL  and 100 mg/mL.  
 
Administration and Compatibility  
Ofatumumab  Injection,  20 mg/mL  and 100 mg/mL  for intravenous  administration must  be diluted with 
0.9%  w/v Sodium   Chloride  for Injection.   Directions  for administration  are provided in section  6.1.1.  
Ofatumumab  must  be administered separately  from other medications.  
 
Toxicity:  Infusion reactions,  neutropenia,  pneumonia,  pyrexia,  cough,  diarrhea,  anemia,  fatigue,  dyspnea,  
rash,  nausea,  bronchitis, and upper respiratory  tract infections. Detailed  above.  
 
10.2 Etoposide  (Vespid®;  VP-16) 
Action: inhibition of Topoisomerase II results  in metaphase arrest, predominantly G2.  
Availability:  commercially  available.  
Preparation:  supplied  as a liquid  in mutli- dose vials (100 mg/5ml;  150 mg/7.5 ml; 500 mg/25 ml; 1,000  
mg/50 ml). 
Storage and Stability:  unopened vials are stable for 24 months  at room  temperature.  Vials  opened and 
diluted to a concentration  of 0.2-0.4 mg/ml  are stable for 96 and 24 hours,  respectively,  at room  
temperature in  glass  or plastic  containers.  
Administration:  Can be administered undiluted intravenously  over 4 hours  with NS piggyback.  
Toxicity:  fever,  hypotension,  bronchospasm,  acidosis,  and hypersensitivity  reactions  during  
administration,  bone marrow  suppression,  stomatitis  and enteritis,  skin reactions,  elevated liver tests,  
rarely  paresthesias,  nausea,  vomiting,  and alopecia.  
 
 
10.3 G-CSF (Filgrastim;  Neupogen®)  
Action:  stimulates  the proliferation and differentiation of myeloid  progenitor  cells,  stimulates  their end-cell 
functional  activation,  and mobilizes  hematopoietic stem  cells into the peripheral circulation.  
Availability:  G-CSF is commercially  available.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  28  
  
 
Preparation:  Supplied  in 300 and 480 mcg vials containing 1.0 and 1.6 ml of sodium  acetate,  respectively.  
Storage and Stability:  Vials  should  be stored at 2-8o C. Avoid  freezing or shaking of vials.  Vials  are 
stable  at room  temperature for 6 hours.  
Administration:  SQ or IV administration is permitted.  
Toxicity:  mild to severe bone pain,  leukocytosis,  pain at injection  site, anaphylaxis,  Sweet’s  syndrome,  
hypotension,  splenomegaly,  splenic  pain.  
 
10.4 Cytarabine (Cytosar -U®; Ara-C; Cytosine  arabinoside)  
Action:  as a pyrimidine  analog,  cytarabine is incorporated  into DNA  and competitively  inhibits  DNA  
polymerase and thus inhibits  DNA  synthesis.  
Availability:  commercially  available.  
Preparation:  supplied as 100, 500 mg, 1,000 mg,  and 2,000 mg vials.  
Storage and Stability:  diluted  solutions  are stable  for at  least 192 hours  at room  temperature.  
Administration:  dilute  with 0.9%  benzyl  alcohol  (5 ml for 100-1,000 mg cytarabine;  20 ml for 2,000 mg 
cytarabine)  plus 50-100 ml D5W  or NS for 1-2 hour IV infusions  or in 500-1,000  ml D5W  or NS for longer  
IV infusions. May be given SQ (10-30 mg) in 1 ml NS. 
Toxicity:  myelosuppression,  central  nervous  system  toxicity  (doses  ≥500  mg/m2,  especially  when  
creatinine clearance is <60 cc/min;  see Sections  9.4.3 and 10.6.2),  stomatitis, nausea,  emesis,  non- 
cardiogenic  pulmonary edema, keratoconjunctivitis,  cutaneous  toxicity,  alopecia, hepatic dysfunction.  
 
 
 
11 STATISTICAL  CONSIDERATIONS  
 
This is a single -institution,  single- arm, open -label  Phase II study  of Ofatumumab in combination with 
etoposide and high- dose  cytarabine as an intensive consolidation and stem  cell mobilization regimen in 
patients  with relapsed/refractory  diffuse  large B- cell lymphoma.  The primary  efficacy  endpoint  of the 
study  is the mobilization- adjusted complete response  rate (maCR)  which  is defined as: the proportion of  
patients  achieving complete response to the treatment  upon successful  stem  cell mobilization,  defined as  
at least  2 x10^6 CD34+cells/Kg of actual  body  weight.  Secondary  endpoints  include time to neutrophil  
and platelet  engraftment  following  ASCT,  PFS in this high- risk patient  population  and other  survival -time 
measures  of clinical  efficacy,  i.e. OS, TTP,  EFS,  and CR/Pr  proportion at day +90. Our study  will also 
measure the FDG -PET conversion rate from PR to CR following  OVA and correlate post-OVA PET 
results  with PFS,  TTP,  and OS. We will examine potential  relationships  between Ofatumumab 
concentration  at selected time points  and PFS,  TTP,  OS. We will perform  MRD  testing at baseline,  at the 
time of stem  cell collection,  and following  ASCT,  and will correlate the results  to clinical endpoints.  
Finally,  safety  will be evaluated with regard to infusion- related reactions,  B-cell number,  
hypogammaglobulinemia,  and long- term hematologic  toxicity.  
 
11.1 Sample  Size 
Patients  who have received a single  infusion of study  drug (day 0 of OVA)  will be included in the 
statistical  analyses.  We are planning to accrue  24 subjects  over the course of 2 years  with an additional  
2-year follow -up. In terms  of the composite primary  endpoint,  the historical  CR rate after 2 cycles  of 
salvage therapy  among  high risk, rituximab refractory  patients  is between 25% and 50% of the overal  
responses [i.e CR/(CR+PR].[8, 19, 20] Furthermore,  the chance of a mobilization failure  among complete 
and partial  responders  observed in the CORAL  study  is 15%.[9]  We thus expect  the null value of the 
composite endpoint  of maCR  to be 25% (~40%  CR-15% mobilization  failure).  Given  the excellent  
historical CR rates  with intensive consolidation and the very low risk of mobilization  failures,  we expect  
the alternative maCR  rate to be 50%.  Based  on the exact  probability  with type I error  of 10% and 1- sided 
test, a sample size of N=24  in the single arm study  will have > 80% power  to detect  the maCR rate for the 
following  hypothesis:  H0: p0<25%  (40%CR/15%mobilization- failure)  vs Ha: p1>50%  
(55%CR/5%mobilization- failure under  OVA).  The following  table shows  statistical  power  for the test of 
the null hypothesis  under  the assu med maCR  of 25% and for various  mobilization- adjusted complete  
response rates  with 24 subjects  (alpha=10%  under 1- sided exact test):  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  29  
  
 
 
maCR  rate Statistical  Power  
25% vs 40% 51% 
25% vs 45% 70% 
25% vs 50% 84% 
25% vs 55% 93% 
25% vs 60% 97% 
 
An interim analysis  for futility  and safety  will be  performed when 12 subjects  are enrolled.  We will define 
the futility  as >50%  stem  cell mobilization failure as  excessive and unacceptable. If  six or fewer  (< 50%)  
subjects  have adequate stem  cell mobilization,  the enrollment will not continue and the study  will be 
closed for treatment  futility.  Otherwise  we will enroll 12  additional patients to complete study  for full  maCR  
efficacy analysis.  At the same time as the interim  analysis  for futility, we will also perform  an interim  
evaluation for safety, which is defined as >30%  SAE as too toxic  and unacceptable.  If 4 or more  (>30%)  
of the first 12 patients treated are observed to have protocol -defined unacceptable toxicity,  the study  will 
be closed for lack of safety. If the stem  cell collection success rate is less than 50%, the probability  of 
early stopping due to  futility  is 61%.  If the toxicity  rate is  greater than 30%,  the probability of  early  
stopping due to safety  is 64%.  
 
11.2 Statistical  Methods  
The results  of this single -institution  study  will be evaluated and reported as follows.  Proportions  will be 
compared with the chi square test. Time -to-event  variables  will be analyzed with the Kaplan- Meier  
method and compared across subgroups  with the log- rank test. 
 
Primary  Analysis 
 
For primary efficacy analysis, the proportion of  stem  cell mobilization,  the proportion of complete  
response and the proportion of  mobilization -adjusted complete response will be analyzed and reported 
separately  and collectively.  Descriptive statistics  with frequency  and proportion with exact  95% 
confidence intervals will be  reported for the  study.  The acceptable stem  cell collection  is defined as a 
minimum CD34  cell dose of > 2 x 10 x 106/kg (actual  body weight)  and optimal stem  cell collection as a 
CD34 cell dose of  > 5 x 106/kg (actual  body  weight). Subjects  who require use of plerixafor  or an 
autologous  bone marrow  harvest  are considered mobilization failures  and will be treated as  non- 
responders, ie.  they will be included in the denominator  when calculating  the percentage for the primary  
efficacy analysis.  The CR  rate will be calculated  based on the PET/CT  scan  following  2 cycles  of salvage  
therapy.  
 
Secondary  Analyses  
 
Progression free  survival  (PFS),  defined the time from day  0 until lymphoma progression, receipt  of 
anti-lymphoma therapy  (except  for planned post-ASCT  radiotherapy),  or death as a result  of any  cause,  
will be summarized using Kaplan- Meier  quartile estimates  along with  two-sided 95%  confidence intervals.  
If a subject  receives  subsequent  anti-lymphoma  therapy prior  to the date of  documented progression or 
death, progression free-survival will be  censored at the last  adequate assessment  prior to the initiation  of 
that anti -cancer  therapy.  Otherwise,  if the subject  does  not have a documented date of  progression or  
death, progression -free survival  will be censored at the date of the last  adequate assessment. No formal  
hypothesis test will be performed for significance.  
 
Stem cell  engraftment rate  will be  evaluated for  neutrophil  and platelet  following  successful  mobilization.  
Failures  of stem  cell collection will be considered as non-responders. Neutrophil  engraftment is  defined as  
the first  day of  3 consecutive days  with absolute neutrophil count  of >500 cells/uL.  Platelet  engraftment will  
be defined as  the first  of three  consecutive measurements  for which the platelet count  was >      
20,000/uL, and must  be at  least 24 hours  following  the last platelet  transfusion.  Engraftment  rate will be 
reported  separately  for neutrophil and platelet. Descriptive statistics  with proportion and frequency  will be 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  30  
  
 
used and 95% confidence intervals  will also  be reported.  No formal  hypothesis test  will be performed for 
significance.  
 
The Time to progression, defined as the time from study  entry until documented lymphoma progression 
or receipt  of anti-lymphoma  therapy  or death,  will be  summarized  descriptively  using Kaplan- Meier  
quartiles, along with two -sided  95% confidence  intervals,  for each  of the cohorts.  Only the subset  of 
subjects  who show  a complete or  partial  tumour  response will be included in  this analysis.  Censoring 
rules  follow the rules  for PFS. No formal hypothesis  test will be performed for significance.  
 
Overall survival (OS):  OS, defined as the time to death for any reason,  will be summarized  using 
Kaplan- Meier  quartile  estimates  along with two -sided 95%  confidence intervals. OS  will be censored 
using the date of  last known contact  for those who are alive at  the time of analysis.  No formal  
hypothesis test will be performed for significance.  
 
Other  secondary  analyses  will include the  association between FDG -PET conversion,  Ofatumumab  
concentration,  the effect of OVA  and the clinical outcomes  such  as PFS, OS  and Time to progression 
(duration of response).  
 
11.3 Accrual  and Estimated  Duration  of Study  
As a tertiary  care referal  BMT  center  in Northern  Califronia,  we perform  approximately  15 such  
transplants  in this patient  population annually  and we expect  to enroll  most  of our patients  on this study.  
There  are no competing studies  currently,  in development,  or planned.  Thus  the study  should complete 
accrual within 24- 30 months  of initiation.  
 
11.4 DLBCL  Subtyping 
 
Tumor  tissue  and peripheral  blood stem  and mononuclear  cells will be collected for DLBCL  subtyping.  
The best way to subtype DLBCL   is currently  in evolution.  For this study,  a combination  of gene  
expression profiling  (GEP)  and immunohistochemistry  (IHC) will be utilized  to distinguish different  disease 
entities.  
 
11.5 Minimal Residual  Disease  Testing  
 
MRD  assessments will take place in collaboration with Sequenta (South San Francisco,  CA). For each  
patient  the cancer -specific  IgH rearrangement  will be identified through the assessment  of a diagnostic  
sample. The diagnostic  sample will be the positive lymph  node (frozen  or archived FFPE)  or bone marrow  
aspirate sample  (whole  aspirate,  frozen cells,  or clots)  in patients  with an involved marrow.  All the IgH 
sequences  are amplified from the diagnostic  samples  and the product  is subjected to DNA  sequencing.  
The cancer -specific  sequence is expected  to be present  at high frequency  (>10%)  in contrast  to most  
other  sequences  present  at very low level (<0.1%).  The cancer -specific  sequence is then readily  
measured for each  patient  by determining the level of that sequence in a subsequent  sample.  This is 
done by amplifying all the IgH sequences  from the relevant  samples  and subjecting the product  to deep  
sequencing  (1M reads  or more).  The level of the cancer -specific  sequence can then be determined at 
very high sensitivity  (due to the depth  of sequencing)  and specificity  (due to the uniqueness  of each  IgH 
sequence).  We will determine the feasibility  of this methodology  in our patient  population.  We will 
measure the MRD  conversion  rate following  OVA and correl at e this with clinical outcomes.  Additionally,  
we will perform  MRD  surveillance following  ASCT  and correlate it with Ofatumumab  pharmacokinetics  
and relapse.  
 
 
 
11.6 Data  Safety  Monitoring Plan:  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  31  
  
 
The study  data will be reviewed  twice  a month by the PI and study  coordinator . Safety  data and 
specifically  SAEs and  grade 3- 5 AEs  will be reviewed at the Hematology  Site Committee twice a month.  
 
 
Monitoring and Reporting Guidelines  
Investigators  will conduct  continuous  review  of data and patient  safety  at weekly  Transplant  Meeting or 
Site Committee  meetings  where the results  of each  patient’s  treatment  are discussed.  The discussion  will 
include,  the number  of patients  enrolled,  significant  toxicities,  stem  cell mobilization,  and observed  
responses. The study  coordinator  will keep a log of subject(s)  on study and grade  3-5 AE’s and SAE’s  will 
be entered in the HDFCC  Oncore  database.  
 
Interim  Analysis  
An interim analysis  for futility  and safety  will be  performed when 12 subjects  are enrolled.  We will define 
the futility  as >50%  stem  cell mobilization failure as  excessive and unacceptable. If  six or fewer  (< 50%)  
subjects  have adequate stem  cell mobilization,  the enrollment will not continue and the study  will be 
closed for treatment  futility.  Otherwise  we will enroll 12  additional patients to complete study  for full  maCR  
efficacy analysis.  At the same time as the interim  analysis  for futility, we will also perform  an interim  
evaluation for safety, which is defined as >30%  SAE as too toxic  and unacceptable.  If 4 or more  (>30%)  
of the first 12 patients treated are observed to have protocol -defined unacceptable toxicity,  the study  will 
be closed for lack of safety. If the stem  cell collection success rate is less than 50%, the probability  of 
early stopping due to  futility  is 61%.  If the toxicity  rate is  greater than 30%,  the probability of  early  
stopping due to safety  is 64%.  
 
Serious  Adverse  Event  Reporting  
Serious  Adverse Event  reporting  will be in accordance with the UCSF -Committee  on Human  Research  
Regulations  and Code of Federal  Regulation Title 21 Volume 5 Part 312.32.  In addition,  SAEs  will be 
entered into the Oncore  database.  
 
UCSF  CHR website for guidance in reporting serious  adverse events  
http://www.research.ucsf.edu/chr/Guide/chrA_AE.asp  
 
FDA website for guidance in reporting serious  adverse  events  
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=312.32  
 
MedWatch forms  and information:  
http://www.fda.gov/medwatch/getforms.htm  
 
Serious  Adverse events will  be reported on the MedWatch form.  A copy of the MedWatch report and CHR  
forms  must  be sent to CCC -DSMC  at Box 1297.  The date the SAE was sent to all required reporting  
agencies  will be documented on Oncore;  hard copies  of the report  will be maintained in the regulatory  
files. 
 
 
 
12 Data  Management  and Study  Termination  
12.1 Data  and Protocol  Management  
 
1. Data Management : All patients  enrolled on trial will be given a study -specific  registration number.  
The registration number  will be used to identify  all patients  on trial.  
2. Protocol  Compliance : Patients  and their medical  records  will be reviewed  every  other  week  until 
the first 30 days post-transplantation and otherwise monthly  by the study  investigators.  Study  
endpoints  will be reviewed  and documented.  Any questions  regarding serious  adverse events  and 
toxicity  should be discussed  with the study  chairman directly.  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  32  
  
 
3. Case Report  Forms : Clinical data  will be recorded  on  case  report  forms.   CRF’s  should be 
completed on a timely  basis.  The principal  investigator  will review  all CRF’s.  
4. Accuracy  of Data Collection : The UCSF  Cancer  Center  DSMB,  UCSF  CHR,  IBMTR  or individual  
government  board may review  the data from this study  for accuracy.  The UCSF  DSMB will be the 
final arbiter of  eligibility, toxicity  and other endpoints  should a difference  of opinion exist.  
 
12.2 Termination of Study  
 
UCSF retains  the right  to terminate the study  at any time.  
 
UCSF  retains  the right to terminate an individual  study  patient’s  participation  in the study  due to the 
following:  
1. Noncompliance with study  procedures  
2. Concomitant use  of any study  drug or  procedure without  prior approval  from the Principal  
Investigator  
3. Unanticipated adverse medical  experiences  in this or other  studies  indicating a potential  health 
hazard caused by  the study  
4. Study  patient’s  withdrawal  from protocol  
 
 
13 Study Finances  
13.1 Funding Source  
This study  is financed by  NOVARTIS.  
 
13.2 Conflict  of Interest  
Any investigator  who has a conflict  of interest  with this study  (patent  ownership,  royalties,  or financial  gain 
greater  than the minimum  allowable  by their institution,  etc.) must  have the conflict reviewed by a properly  
constituted Conflict  of Interest  Committee  with a Committee- sanctioned  conflict  management  plan that 
has been reviewed and approved by the study  sponsor  prior to participation  in this study.  Subject  
Stipends  or Payments  
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  33  
  
 
 
14 References  
 
1. Coiffier,  B., et al., CHOP  chemotherapy  plus rituximab  compared with CHOP  alone in elderly  
patients with diffuse large-B- cell lymphoma.  N Engl J Med,  2002.  346(4):  p. 235-42. 
2. Habermann,  T.M., et al., Rituximab -CHOP  versus  CHOP  alone or with maintenance rituximab in 
older patients  with diffuse large  B-cell lymphoma.  J Clin Oncol,  2006.  24(19): p. 3121- 7. 
3. Pfreundschuh,  M., et al., CHOP -like chemotherapy  plus rituximab  versus  CHOP -like 
chemotherapy  alone in young patients  with good -prognosis  diffuse large -B-cell lymphoma:  a 
randomised controlled trial by the MabThera International  Trial (MInT) Group.  Lancet  Oncol,  
2006. 7(5): p.  379-91. 
4. Philip,  T., et al., Autologous  bone marrow  transplantation as compared with  salvage  
chemotherapy  in relapses  of chemotherapy -sensitive  non-Hodgkin's  lymphoma.  N Engl J Med,  
1995. 333(23): p.  1540 -5. 
5. Hahn,  T., et al., The role of cytotoxic therapy  with hematopoietic  stem cell transplantation in the 
therapy  of diffuse  large cell B-cell non-Hodgkin's  lymphoma:  an evidence -based review.  Biol 
Blood Marrow  Transplant,  2001. 7(6): p. 308-31. 
6. Weaver,  C.H.,  et al., High-dose  fractionated  total-body  irradiation,  etoposide,  and 
cyclophosphamide followed  by autologous  stem- cell support  in patients   with  malignant  
lymphoma. J Clin Oncol,  1994. 12(12):  p. 2559- 66. 
7. Guglielmi,  C., et al., Time  to relapse has prognostic  value  in patients  with aggressive lymphoma  
enrolled onto the Parma trial.  J Clin Oncol,  1998.  16(10): p.  3264 -9. 
8. Hamlin,  P.A.,  et al., Age-adjusted International  Prognostic  Index  predicts  autologous  stem cell 
transplantation outcome for patients  with relapsed  or primary  refractory  diffuse  large B- cell 
lymphoma. Blood,  2003.  102(6): p. 1989 -96. 
9. Gisselbrecht,  C., et al., Salvage Regimens  With Autologous  Transplantation for Relapsed Large 
B-Cell Lymphoma in the Rituximab Era.  J Clin Oncol,  2010.  
10. Damon,  L., et al., Impact  of intensive PBSC  mobilization therapy  on outcomes  following auto- SCT 
for non -Hodgkin's  lymphoma. Bone Marrow  Transplant,  2008. 42(10):  p. 649-57. 
11. Juweid,  M.E., et al., Response assessment  of aggressive non-Hodgkin's  lymphoma by integrated  
International  Workshop  Criteria  and fluorine -18-fluorodeoxyglucose positron emission  
tomography.  J Clin Oncol,  2005. 23(21): p. 4652 -61. 
12. Cheson,  B.D.,  et al., Revised  response criteria  for malignant  lymphoma.  J Clin Oncol,  2007.  
25(5): p. 579 -86. 
13. Derenzini,  E., et al., Pretransplantation positron emission tomography  scan  is the main  predictor  
of autologous  stem cell transplantation outcome in aggressive B- cell non-Hodgkin lymphoma.  
Cancer, 2008.  113(9): p.  2496- 503. 
14. Filmont,  J.E., et al., Value of F-18 fluorodeoxyglucose positron emission tomography  for 
predicting the clinical outcome of patients  with aggressive lymphoma prior to and after autologous  
stem- cell transplantation.  Chest,  2003. 124(2): p. 608-13. 
15. Cremerius,  U., et al., Pre-transplant  positron  emission  tomography  (PET)  using  fluorine -18-fluoro- 
deoxyglucose  (FDG) predicts  outcome in patients  treated with high-dose  chemotherapy  and 
autologous  stem cell transplantation for non-Hodgkin's   lymphoma.  Bone Marrow  Transplant,  
2002. 30(2): p.  103-11. 
16. Svoboda,  J., et al., Prognostic  value of FDG -PET scan  imaging in lymphoma patients  undergoing  
autologous stem cell transplantation.  Bone Marrow  Transplant,  2006.  38(3): p.  211-6. 
17. Schot,  B.W.,  et al., The role of serial pre-transplantation positron emission  tomography  in 
predicting progressive disease in  relapsed lymphoma.  Haematologica, 2006.  91(4):  p. 490-5. 
18. Spaepen,  K., et al., Prognostic  value of pretransplantation positron emission tomography  using 
fluorine 18-fluorodeoxyglucose in patients  with aggressive  lymphoma treated  with high-dose  
chemotherapy  and stem cell transplantation.  Blood,  2003. 102(1): p.  53-9. 
19. Vellenga,  E., et al., Rituximab improves  the treatment  results  of DHAP -VIM-DHAP  and ASCT  in 
relapsed/progressive aggressive CD20+  NHL:  a prospective  randomized HOVON  trial. Blood,  
2008. 111(2): p.  537-43. 
Version  01-17-2017 
 Protocol  #112525  
Dr. Charalambos  Andreadis  OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  34  
  
 
20. Sud, R. and J.W. Friedberg,   Salvage therapy  for relapsed or refractory  diffuse large  B-cell 
lymphoma: impact  of prior  rituximab.  Haematologica, 2008.  93(12):  p. 1776 -80. 
21. Moskowitz,  C.H., et al., High-dose  chemo- radiotherapy  for relapsed  or refractory  Hodgkin  
lymphoma and the significance  of pre-transplant  functional  imaging.  Br J Haematol,  2010.  148(6):  
p. 890-7. 
22. Teeling,  J.L., et al., The biological  activity  of human  CD20  monoclonal  antibodies  is linked  to 
unique epitopes  on CD20.  J Immunol,  2006.  177(1): p. 362-71. 
23. Teeling,  J.L., et al., Characterization of new human  CD20  monoclonal  antibodies  with potent  
cytolytic activity  against  non-Hodgkin lymphomas.  Blood, 2004.  104(6): p.  1793- 800. 
24. Ofatumumab Investigator's  Brochure,  Version 4.0. 2011.  
25. Bleeker,  W.K.,  et al., Estimation of dose requirements  for sustained in vivo activity of a 
therapeutic  human anti -CD20  antibody.  Br J Haematol, 2008.  140(3): p. 303-12. 
26. Coiffier,  B., et al., Ofatumumab monotherapy  for treatment  of patients  with relapsed/progressive  
Diffuse  Large B- Cell Lymphoma:  Results  of a mutlicenter  phase II study.  Blood,  2010.  116: p. 
abst 3955.  
27. Cilessen,  S.A.G., W.J. Mackus,  and K.C. Castricum,  Chemotherapy -refractory  diffuse large  B-cell 
lymphomas  are effectively  killed  by ofatumumab- induced complement -mediated cytotoxicity.  
Blood, 2007.  110: p. abstr  2346: 694a.  
OVA in High -Risk Relapsed/Refractory DLBCL  Page 35  
  
 
 
15 Attachments  
15.1 Study  Procedures  
 
Procedures  Registration  Salvage  
Assessment  OVA  Post ASCT  Follow -up Long term follow -up 
Days:    0 1-4 7 14 21 42 Days  +30’,  +60’ 
post ASCT  Day +90’ 
post ASCT  Month 6 
post ASCT  Month 12 
post ASCT  Month 24 
post ASCT13 
Informed Consent  X             
Demography  X             
Medical  History  X X X     X X X X X X 
Disease  History  X             
Therapy  History  X             
Efficacy  Assessments               
Bone  marrow  biopsy   X      X1  X1    
CT  X      X  X X X X 
PET  X      X  X X7   
LP2  X            
Disease Status  & survival   X      X  X X X X 
Safety  Assessments               
Physical  Exam  X X X     X X X X X X 
ECOG  X       X X X X X X 
Height  X             
Weight  X             
Vital Signs  X  X X X X X X X X X X X 
12-lead ECG   X            
Echo  or MUGA   X            
PFTs  with DLCO   X        X    
Adverse  Events    X X X X X X X X X X X 
Concomitant  Therapy  X X X X X X X X X X X X X 
Study  Medication               
Ofatumumab    X  X X X       
Etoposide     X          
Cytarabine     X          
G-CSF     X3 X3 X3       
 
Version 01-17-2017 Protocol  #112525  
Dr. Charalambos  Andreadis  
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  36  
  
 
Procedures  Registration  Salvage  
Assessment  OVA  Post ASCT  Follow -up Long term follow -up 
Days:    0 1-4 7 14 21 42 Days  +30’,  +60’ 
post ASCT  Day +90’ 
post ASCT  Month 6 
post ASCT  Month 12 
post ASCT  Month 24 
post ASCT13 
Lab Assessments               
Hematology  X X X X4 X4 X4 X4 X X X X X X 
Chemistry  X X X X5 X5 X5 X5 X X X X X X 
Coags  X  X           
Serum  Pregnancy  Test X             
Hepatitis B&C  antibodies6 X             
HBV DNA  PCR6 X       X X X X X X 
CD19+  B-Cells    X     X  X X X X 
Quant  Igs   X     X  X X X X 
Ofa PK       X8 X  X X X X 
Tumor  Tissue  Collection  X9             
PBMC  Aliquot        X10       
MRD  Testing  on Blood  X11 X11      X11  X11 X11 X11 X11 
MRD  Testing  on PBMC  
from apheresis        X12       
1:BM performed on day 42 and +90’ If positive at salvage  assessment  
2: LP performed only if previously positive or for  suspected CNS  involvement  
3: Starts  day 14 and stops when  stem  cell collection  complete 
4: Daily  CBC with  differential  until leukapheresis completed.  
5: Daily: electrolytes,  creatinine. Twice weekly: bilirubin,  alkaline phosphatase, AST, ALT, LDH.  Stop when leukapheresis completed  
6: Subjects  who are HBcAb positive  must undergo at least every 2 month HBV DNA  PCR testing during the treatment course.  Monitoring must also occur during the follow -up period for  a 
minimum of 6 months after the last dose as long as the subject  remains  in the study  at a minimum frequency of every 2 to 3 months.  
7: PET will be repeated at 6 months if positive at day +90’ evaluation 
8: Within  24 hours after end of infusion on day 21.  
9: 20 unstained slides  or tissue block from the time of relapse (preferred)  or initial diagnosis, if available.  
10: 4 cryovials with  PBMC  aliquot  will be stored at time of first apheresis. Apheresis  may occur on or after  day 21.  
11: MRD determination will be performed on 10 mL of  peripheral blood at the timepoints indicated.  
12. Some apheresis product  (4cc)  will be sent for MRD testing.  
13: Patients  who do not  progress in the first 24 months,  will be followed for disease status  and survival  every 6 months,  until 5 years.   See Section 6.0.  
 
  
 
Version 01-17-2017 Protocol  #112525  
Dr. Charalambos  Andreadis  
OVA in High -Risk Relapsed/Refractory DLBCL  Page 37  
  
 
 
15.2 Calculation  of sAAIPI  
This is calculated at the time of progression or relapse and prior to initiation  of second- line (salvage)  
chemotherapy.  
 
-Serum  LDH > upper  limit of  normal  
 
-ECOG  PS ≥ 2 
 
-Stage  ≥ III 
 
  
 
     
 
    
 
     
 
     
 
    
 
     
 
     
 
 
 
Version 01-17-2017 Protocol  #112525  
Dr. Charalambos  Andreadis  
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  38 
Version  01-17-2017 Protocol  #112525  
Dr. Charalambos  Andreadis   
  
 
 
15.3 High  Dose  Therapy with  Stem  Cell Rescue  (CBV)  
 
Carmustine  15 mg/kg  IV (maximum  dose,  550 mg/m2)  on Day  -6. 
 
a. Carmustine dose  should be calculated based on corrected weight  calculated as ideal  weight  plus 
25% of the difference  between actual  and ideal  weight.  Use actual  weight  if it is lower  than ideal 
weight.  
b. Each  Carmustine  vial is reconstituted with 3 ml absolute ethanol  and 27 mL sterile  water.  Total  
Carmustine dose is diluted in  1000 ml D5W  or NS.  
c. Administer  over 2-3 hours  in a light-protected glass  bottle or Excel  bag. Maximum  infusion  rate is 180 
mg/m2/hour.  
d. Premedication with  diphenhydramine 50 mg IV 30 minutes  prior to Carmustine is  recommended.  
 
Etoposide  60 mg/kg  IV over  4 hours  on Day -3. 
 
a. Etoposide dose  should be calculated  based on corrected weight  calculated  as ideal  weight  plus 25% 
of the difference  between actual  and ideal  weight.   Use actual  weight if  it is lower  than ideal  weight.  
b. Etoposide should be given undiluted over  4 hours  and piggybacked into NS at 1000 ml/hour.  
c. Premedication with hydrocortisone 100 mg IV to be repeated in 2 hours  during the infusion,  
acetaminophen 650 mg PO, and cetirizine  10 mg PO is recommended.  Meperidine 25 mg IV q1 hour 
prn for  rigors  may be administered up to 3 doses.  
d. Febrile  reactions  should be treated with  hydrocortisone and diphenhydramine as is necessary.  
e. Hypotension may occur  during the Etoposide administration.  If this happens,  first pause the infusion 
and restart  when the blood pressure recovers.  If hypotension persists  or recurs,  then give Dopamine  
IV to maintain the blood pressure  in order  to complete the Etoposide infusion.  If hypotension persists,  
abort the Etoposide infusion.  
f. Etoposide  Phosphate  (Etopophos): may be substituted for etoposide for patients  > 60 years  old or 
for younger  patients  as clinically  indicated.  Etopophos  60 mg/kg  IV over 3-4 hours.  Mix in 250-500 
milliliters  0.9%NaCl  for concentration  > 0.1 mg/ml.  Hydrocortisone  100 mg IV and cetirizine  10 mg 
PO will be given prior to infusion.  Febrile  reactions  should be treated with additional  hydrocortisone  
and diphenhydramine as is necessary.  
 
Cyclophosphamide  100 mg/kg  IV over  2 hours  day -2. 
 
a. Cyclophosphamide and Mesna dose should be calculated based on corrected weight  calculated as 
ideal  weight  plus 25% of the difference  between actual  and ideal  weight.  Use actual  weight  if it is 
lower  than ideal  weight.  
b. One hour before cyclophosphamide begin IV NS plus KCl 20meq/L  to run at 250 cc/hour  to 
continuefor  20 hours after  end of cyclophosphamide infusion,  for a total of  24 hours.  
c. MESNA  120 mg/kg  (corrected weight)  in 1 liter D5W  IV over 24 hours  should begin one hour prior to 
cyclophosphamide infusion for  a total of 24  hours.  
d. Cyclophosphamide should be infused over  3 hours  in 500 mL D5W.  
e. Cyclophosphamide -related gross  or microscopic  hematuria  correlates  with the concentration of drug 
metabolites  in the bladder.  Adequately  hydrate patients  and ensure frequent  voiding.  If hemorrhagic  
cystitis  occurs,  consider  adding bladder  irrigation  (500 cc/hour  sterile  urologic  saline  via a 3- way 
Foley catheter  for 48 hours after cyclophosphamide administration).  
f. Furosemide  may be used for  volume management  per institutional  protocol.  
 
Autologous  peripheral  blood stem  cell infusion  will take place on Day 0. 
 
Peripheral  blood stem  cells should be thawed in a 37˚ water bath and immediately infused intravenously.  
OVA in High -Risk Relapsed or  Refractory  DLBCL  Page  39 
Version  01-17-2017 Protocol  #112525  
Dr. Charalambos  Andreadis   
  
 
Supportive  Care  
 
 G-CSF 5 mcg/kg  SQ daily  (actual  body  weight,  rounded up to vial size)  starting  Day +6’. G- 
CSF should continue daily until the absolute neutrophil  count  exceeds  1500/µl  for 2 consecutive  days  
or > 5000/uL for one day. It should then be stopped  but should be resumed if the ANC  falls to < 
1000/µl.  If G-CSF is resumed it should then be continued until the ANC > 5000/µl.  
 Fluconazole  400 mg PO will be given daily starting from day +1’ and will continue until the 
neutrophils  are at least  > 500/uL.  Equivalent  anti-fungal  prophylaxis  with itraconazole or liposomal - 
based amphotericin product  may be used.  
 Prophylaxis  against  pneumocystis  carinii  will be used.  The regimen of choice  is 
trimethoprim/sulfamethoxosole  (Septra)  DS po bid 2 days/week  starting after engraftment  (ANC  
>1500/uL,  and Platelets  >30,000/uL).  An alternative regimen is  dapsone 100 mg  po daily.  Prophylaxis  
will continue until at  least day +90’  after transplant.  
 Prophylaxis  against  bacterial  infections  should begin when the ANC  is < 500/uL  and continue until the 
ANC  is > 1000/uL. Moxifloxacin  400 mg daily or an equivalent antibiotic is appropriate.  
 Prophylaxis  against  herpes  simplex  and herpes  zoster  with acyclovir  400 mg po bid from day –2 until 
1 year post-transplant  or as per institutional  standard.  Patients  unable to take oral medication should  
receive acyclovir 2 mg/kg  IV q12 h.  
 Patients  should be hospitalized in private rooms  with positive  pressure ventilation and filtered  air 
systems,  when possible.  
 Strict low bacteria diet should be used when ANC < 500/uL.  
 Recommended mouth care:  
 
a. Salt and soda swish  tid 
b. Gel clear  is allowed 
 
 Transfusions : Institution standards  should be followed  for blood product  support.  In lieu of standards,  
packed RBCes  should be given to maintain the hemoglobin > 8.5 gm/dl  or hematocrit  >25%.  Platelet  
should be transfused to keep  the platelet  count  >10-20 x 109/l as per institution  standards.  Blood should  
be filtered  and irradiated (3000 cGy).  